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1. Introduction 
This report is describing the results of the 
eighteenth proficiency test organized by the 
National Food Institute as the EU Reference 
Laboratory for Antimicrobial Resistance (EURL-
AR). This proficiency test focuses on 
antimicrobial susceptibility testing (AST) of 
enterococci, staphylococci and Escherichia coli. 
It is the ninth External Quality System 
Assurance System (EQAS) conducted for these 
microorganisms. 
The aim of this EQAS is to: i) monitor the 
quality of AST results produced by National 
Reference Laboratories (NRL-AR), ii) identify 
laboratories which may need assistance to 
improve their performance in AST, and iii) 
determine possible topics for further research or 
elaboration. 
When reading this report, please take into 
account the following important considerations: 
1) Expected results were generated by 
performing Minimum Inhibitory Concentration 
(MIC) determinations for test strains in two 
different occasions at the Technical University 
of Denmark, National Food Institute (DTU-
FOOD). These results were then verified by the 
United States Food and Drug Administration 
(FDA), Centre for Veterinary Medicine. Finally, a 
fourth MIC determination was performed at 
DTU-FOOD after preparation of the agar stab 
culture for shipment to participants to confirm 
that the vials contained the correct strains with 
the expected MIC values. 
2) The evaluations are based on interpretations 
of AST values determined by the participants. 
This is in agreement with the methods included 
in the EU Decision 652/2013 which are to be 
used for the testing of E. coli and Enterococci 
species and the most recent recommendations 
from EFSA regarding the testing of 
Staphylococcus aureus by AST. The methods 
used by the participants should be reflecting 
those used to report AST data to the European 
Food Safety Authority (EFSA), so that they 
comply with “the main objective of this EQAS; 
to assess and improve the comparability of 
surveillance and antimicrobial susceptibility 
data reported to EFSA by the different NRLs”, 
as stated in the protocol. 
3) Given the EU regulation referring only to the 
use of MIC methods, and the set-up of the 
database, the reporting of Disk diffusion data 
was not allowed.  
4) The EURL-AR network has previously 
agreed on setting the accepted deviation level 
for laboratory performance to 5%. 
Evaluation of a result as “deviating from the 
expected interpretation” should be carefully 
analyzed in a self-evaluation procedure 
performed by the participant right after the 
EQAS trial results are disclosed. Since methods 
used for MIC determination have limitations, it 
is not considered a problem to obtain a one-fold 
dilution difference in the MIC of a specific 
antimicrobial when testing the same strains. 
However, if the expected MIC is close to the 
breakpoint value for categorizing the strain as 
susceptible or resistant, a one-fold dilution 
difference, which is acceptable, may result in 
two different interpretations, i.e. the same strain 
will be categorized as susceptible and resistant, 
which will be evaluated as correct in one case 
and incorrect in the other if the evaluation is 
based on interpretation of MIC values. Since 
this report evaluates the interpretations of AST 
values, some participants may find their results 
classified as wrong even though the actual MIC 
they reported is only one-fold dilution apart from 
the expected MIC. In these cases, the 
participants should be confident about the good 
quality of their performance of AST. In the 
organization of the EQAS we try to avoid these 
situations by choosing test strains with MIC 
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values more distant from the breakpoints for 
resistance, which is not always feasible for all 
strains and antimicrobial combinations. For this 
reasons, the EURL-AR network unanimously 
has established in 2008 that if there are less 
than 75% correct results for a specific 
strain/antimicrobial combination, the reasons for 
this situation must be further examined and, on 
selected occasions explained in details case by 
case, these results may subsequently be 
subtracted from the evaluation report.  
This report is approved in its final version by a 
technical advisory group composed by 
competent representatives from all NRLs who 
meet once a year at the EURL-AR workshop. 
All conclusions presented in this report are 
publically available. However, participating 
laboratories are identified by codes and each 
code is known only by the corresponding 
laboratory. The full list of laboratory codes is 
confidential information known only by relevant 
representatives of the EURL-AR and the EU 
Commission.  
The EURL-AR is accredited by DANAK as 
provider of proficiency testing (accreditation no. 
516); working with zoonotic pathogens and 
indicator organisms as bacterial isolates 
(identification, serotyping and antimicrobial 
susceptibility testing). 
 
2. Materials and Methods  
2.1 Participants in EQAS 2015 
A pre-notification to announce the EQAS 2015 
on AST of enterococci, staphylococci and E. 
coli was sent by e-mail on the 5th May 2015 to 
the designated NRLs in the network (App. 1) 
and including eight additional laboratories 
(Denmark, Iceland, Norway, Serbia, Spain, 
Switzerland, The Netherlands and Turkey). 
These were invited to take part in the EQAS 
2015 on the basis of their participation in 
previous EQAS iterations and/or affiliation to 
the EU network. Finally, the participant 
laboratories in the EQAS represented all EU 
Member States and three laboratories 
represented non-MS Norway, Switzerland and 
 
Figure 1 Participating countries in susceptibility testing of Enterococci, staphylococci and/or E. coli  
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Iceland (App. 2).  
In total, this report includes AST results E. coli 
strains submitted by 31 laboratories, of 
enterococci strains submitted by 27 
laboratories, of staphylococci strains submitted 
by 25 laboratories. The AST data included in 
the report represent all 28 MS in the EU (only 
one set of data per MS were included) and 
additionally includes data from laboratories in 
three non-EU countries (Norway, Switzerland 
and Iceland) (Figure 1). 
 
2.2 Strains  
Bacterial strains included in this EQAS (eight 
enterococci, eight staphylococci and eight E. 
coli) were selected among the DTU-Food strain 
collection on the basis of antimicrobial 
resistance profiles and previously obtained MIC 
values. For quality assurance purposes, one 
strain per each bacterial species tested has 
been included in all EQAS iterations performed 
to date, which represents an internal control. 
AST of the EQAS strains was performed at 
DTU-Food by MIC determination using the 
Sensititre panels from Trek Diagnostic Systems. 
The MIC values obtained (App. 3) were used as 
reference values for this EQAS trial after 
verification performed by the U.S. FDA. Results 
from the following antimicrobials were however 
not verified by FDA: ampicillin and teicoplanin 
for enterococci; meropenem, colistin, temocillin 
and ertapenem for E. coli and sulfamethoxazol, 
tiamulin and trimethoprim for staphylococci. 
After comparison and verification of the MIC 
values obtained at DTU-Food and FDA, the 
strains were inoculated in agar as stab cultures, 
tested another time for AST and additionally for 
homogeneity at the DTU-FOOD laboratory, and 
dispatched to the participating laboratories on 
the 8th June 2015. 
Reference strains E. faecalis ATCC 29212, S. 
aureus ATCC 29213 and E. coli ATCC 25922 
were provided to new participating laboratories 
with instructions to store and maintain them for 
quality assurance purposes and future EQAS 
trials. 
 
2.3 Antimicrobials  
The panels of antimicrobials recommended for 
AST in this trial are listed in Table 1. 
The antimicrobials tested were similar to the 
previous year and adjusted to the EU regulation 
EC652/2013 and in the case of staphylococci to 
the most recent EFSA recommendations. 
Guidelines for performing AST were set 
according to the Clinical and Laboratory 
Standards Institute (CLSI) document – M7-A10 
(2015) “Methods for Dilution Antimicrobial 
Susceptibility Tests for Bacteria That Grow 
Aerobically; Approved Standard - tenth Edition” 
and whenever commercial methods were used, 
the guidelines of the manufacturer should be 
followed. 
MIC results were interpreted by using EUCAST 
epidemiological cut-off values 
(www.eucast.org), as included in the regulation 
referred above or as recommended by EFSA 
and described in the EQAS protocol (App. 4). 
Results of the ESBL confirmatory testing were 
interpreted according to the recommendations 
by EFSA and as referred in the regulation, 
using MIC testing in the second panel of 
antimicrobials which is intended to be tested 
every time a strain was found resistant to either 
cefotaxime, ceftazidime or meropenem in the 
first E. coli panel and interpreted according to 
the protocol, enabling to conclude on the 
strain’s presumptive ESBL/AmpC or 
carbapenemase phenotype. 
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2.4 Distribution 
Protocols and all relevant information were 
uploaded on the EURL-AR website 
(http://www.eurl-ar.eu) thereby EQAS 
participants could access necessary information 
at any time. On the eighth of June 2015, the 
bacterial strains in agar stab cultures were 
dispatched in double pack containers (class UN 
6.2) to the participating laboratories according 
to the International Air Transport Association 
(IATA) regulations as UN3373, biological 
substances category B. 
2.5 Procedure 
The participants were recommended to keep 
the agar stab cultures refrigerated until 
performance of AST according to the 
information posted on the EURL-AR website 
(App. 4b, 4c, 4d and 4e). In addition, 
instructions for interpretation of AST results 
were provided. For interpretation of MIC 
determination results, cut-off values were 
reported in the protocol (App. 4b: Tables 1, 2 
and 3). The EQAS test strains should be 
categorized as resistant or susceptible for every 
antimicrobial that has an available ECOFF. 
The EURL-AR is aware that there are two 
different types of interpretative criteria of 
results, clinical breakpoints and epidemiological 
cut-off values. The terms ‘susceptible’, 
‘intermediate’ and ‘resistant’ should be reserved 
for classifications made in relation to the 
therapeutic application of antimicrobial agents. 
When reporting data using epidemiological cut-
off values, bacteria should be reported as ‘wild-
type’ or ‘non-wild-type’ (Schwarz et al., 2010). 
Table 1. Panels of antimicrobials for susceptibility testing of bacteria included in this EQAS 2015 component 
Enterococci  Staphylococci  Escherichia coli  1st panel 
Escherichia coli  
2nd panel 
Ampicillin, AMP  Cefoxitin, FOX  Ampicillin, AMP  Cefepime, FEP  
Chloramphenicol, CHL  Chloramphenicol, CHL Azithromycin, AZI  Cefotaxime + 
clavulanic acid (F/C)  
Ciprofloxacin, CIP  Ciprofloxacin, CIP Cefotaxime, FOT  Cefotaxime, FOT  
Daptomycin, DAP  Clindamycin, CLN Ceftazidime, TAZ  Cefoxitin, FOX 
Erythromycin, ERY  Erythromycin, ERY  Chloramphenicol, CHL  Ceftazidime, TAZ  
Gentamicin, GEN  Gentamicin, GEN Ciprofloxacin, CIP  Ceftazidime+ 
clavulanic acid (T/C)  
Linezolid, LZD  Linezolid, LZD Colistin, COL  Ertapenem, ETP  
Quinupristin-dalfopristin 
(Synercid), SYN  
Mupirocin, MUP Gentamicin, GEN  Imipenem, IMI  
Teicoplanin, TEI  Quinupristin-dalfopristin (Synercid), 
SYN  
Meropenem, MERO  Meropenem, MERO  
Tetracycline, TET  Sulfamethoxazole, SMX  Nalidixic acid, NAL  Temocillin, TRM 
Tigecycline, TGC  Sulfamethoxazole+Trimethoprim, 
SXT  
Sulfamethoxazole, SMX   
Vancomycin, VAN Tetracycline, TET  Tetracycline, TET   
 Tiamulin, TIA  Tigecycline, TGC   
 Trimethoprim, TMP    
 Vancomycin, VAN   
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To simplify the interpretation of results, 
throughout this report, we will still maintain the 
terms susceptible and resistant, even in cases 
where we are referring to wild-type and non-
wild-type strains. 
All participating laboratories were invited to 
enter the obtained results into an electronic 
record sheet at the EURL-AR web-based 
database designed for this trial through a 
secured individual login and password.  
A record sheet was provided with the protocol, 
including space for reporting the results (MIC 
values in mg/L) obtained for the reference 
strains. These results were compared to the 
quality control ranges reported by CLSI in 
documents VET01 A4 (2013) / M100-S25 
(2015) (App. 5).  
The database was finally closed and 
evaluations were made available to participants 
on the 17th September 2015. 
After this date, the participants were invited to 
login again to retrieve a database-generated 
individual report which contained an evaluation 
of the submitted results including possible 
deviations from the expected interpretations. 
Finally, participants were encouraged to 
complete an evaluation form available at the 
EURL-AR database with the aim to improve 
future EQAS trials 
3. Results 
The participants were asked to report results, 
including MIC values together with the 
categorisation as resistant or susceptible. Only 
the categorisation was evaluated, whereas the 
MIC values were used as supplementary 
information. 
As mentioned in the introduction, the EURL-AR 
network established that data should be 
examined and possibly subtracted from the 
general analysis if there are less than 75% 
correct results for a strain/antimicrobial 
combination in the ring trial. In this respect, we 
have noticed in the raw data analysis at 
database closing that six antimicrobial/strain 
combinations were causing 25% or more 
deviations and these were further analysed in 
this report, and/or excluded from the analysis if 
this was justified. This was the case for strain 
ENT 9.3/tigecycline (29%), ENT 9.4/daptomycin 
(90%) and ENT 9.4/Quinopristin/dalfopristin 
(33%) as well as ST9.4/ciprofloxacin (58%), 
and ST9.5/Quinopristin-dalfopristin (SYN) 
(56%), EC 9.1/meropenem (33%). 
After these results were analyzed, the results 
for the enterococci and staphylococci 
combinations were deleted from the report as 
the cause for these deviations was that the 
expected values were just one step from the 
breakpoint. Thus, these tests results were not 
considered representative of the capacity of the 
laboratories for performing AST and were 
therefore not included in the report and the 
percentages of deviations for the participants 
were recalculated and presented in this report. 
However, in the case of the results of the 
combination EC 9.1/meropenem, the results 
were kept in the report given the importance of 
carbapenemase detection. This is due to the 
the difficulties that arise in the of the phenotype 
of the OXA-48 gene, present in this strain. In 
the monitoring it is considered that the NRLs 
shoul be able to detect it even though it leads to 
reduced susceptibility to carbapenems which is 
at a rather low level and therefore it is 
challenging to detect this resistance. 
3.1 Methods 
As mentioned previously, all results were 
reported using MIC methods as described in 
the regulation. Furthermore, the database was 
designed only to receive data from MIC tests 
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including values and interpretations as well as 
QC data from MIC relevant strains.  
In the EQAS 2015, 27, 25 and 31 participants 
performed AST by MIC determination for 
enterococci, staphylococci and E. coli, 
respectively. 
3.2 Deviations overall 
The list of deviations is illustrated in Appendices 
8a, 8b and 8c. Figure 2 shows the overall 
deviation levels. 
Overall, the percentage of results in agreement 
with the expected values ranged from a 
minimum of 94.4% (strain ST 9.4) to a 
maximum of 100% (strain EC 9.7), as shown in 
Table 2. The Enterococci trial resulted in the 
highest percentage of correct results, which 
was at 98.7%, whereas it was only very slightly 
lower for both E. coli and staphylococci at 
98.6% in general terms. The results for the 
Table 2. Total number of antimicrobial susceptibility tests (AST) performed for each EQAS 2015 strain and percentage 
(%) of correct results 

















ENT-9.1 278 273 98.2% ST-9.1 316 314 99.4% EC 9.1 591 557 94.2% 
ENT-9.2 279 275 98.6% ST-9.2 313 310 99.0% EC 9.2 431 429 99.5% 
ENT-9.3 255 254 99.6% ST-9.3 314 312 99.4% EC 9.3 641 637 99.4% 
ENT-9.4 257 254 98.8% ST-9.4 288 272 94.4% EC 9.4 646 641 99.2% 
ENT-9.5 296 290 98.0% ST-9.5 295 291 98.6% EC 9.5 646 641 99.2% 
ENT-9.6 279 276 98.9% ST-9.6 314 309 98.4% EC 9.6 418 407 97.4% 
ENT-9.7 277 272 98.2% ST-9.7 315 313 99.4% EC 9.7 649 649 100.0% 
ENT-9.8 278 276 99.3% ST-9.8 314 313 99.7% EC 9.8 646 642 99.4% 
*ENT, enterococci; ST, staphylococci; EC, Escherichia coli.  
 
Figure 2 Overview of the percentages of deviations from expected results obtained in different EQAS iterations for the 
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internal control strains were at similar levels as 
in 2014 for the Enterococcus (2.0%; same as 
2014) and E. coli strains (0.6% vs 0.4% in 
2014), but higher than previously for the 
Staphylococcus internal control strain (5.6% vs 
2.5% in 2014) (Figure 2). 
Detailed analyses of the results obtained for 
each species are reported in the following 
subchapters. 
3.2.1 Enterococci  
Analysis of results from the Enterococci trial 
showed that three antimicrobial/strain 
combinations had more than 25% deviations 
due to expected MIC being one dilution step 
from the breakpoint. This was the case of 
combination EURL ENT 9.3 and tigecycline, the 
combination ENT 9.4 and daptomycin and ENT 
9.4 and quinopristin/dalfopristin (SYN). For ENT 
9.3 and tigecycline, 21 laboratories uploaded 
results and of these 29% (n=6) have obtained a 
deviation by considering it as resistant. This 
strain had an expected result of “S” and an 
expected MIC value of 0.25 mg/L which is just 
below the breakpoint. All six laboratories having 
a deviation had submitted a MIC value of 0.5 
mg/L (just one step above).  
Similarly for ENT 9.4/daptomycin 22 
laboratories uploaded results and from these a 
20 (91%) considered the strain as susceptible 
while it was expected interpretation was set as 
resistant. The expected value of the MIC was 8 
mg/L and 10 participants found the MIC to be at 
4 mg/L while 2 observed it at 2 mg/L and only 
one at 1 mg/L.  
The third combination of enterococci which was 
found problematic was ENT 9.4 and 
Quinopristin/dalfopristin with a deviation level at 
33%. In this case, 21 results were uploaded 
and from these, seven were found deviating 
due to finding the MIC at 8 mg/L and 
interpreting it as “R” which was just one step 
deviation from the expected MIC at 4 mg/L and 
corresponding susceptible interpretation 
whereas the remaining fourteen had the correct 
interpretation obtained with either observing 
and MIC of 4 mg/L in thirteen cases or 2 mg/L 
in one case. 
These results were omitted from the 
calculations in this report as they do not reflect 
the capacity of the laboratories to perform AST. 
Twenty-seven laboratories, representing 27 
countries (24 MS and three non-EU countries) 
uploaded results for the enterococci trial. The 
Enterococci trial had in general excellent results 
with 98.7% of the AST results interpreted 
correctly.  
Results deviating from expected interpretation 
subdivided by strain showed that the 
percentage of deviations ranged from 0.4% 
(ENT 9.3) to 2.0% (ENT 9.5) (Figure 3).  
Analysis of the results according to the tested 
antimicrobials showed that the highest 
percentages of deviation from expected 
interpretations were obtained in testing 
susceptibility to tigecycline (11.0%) and 
quinopristin-dalfopristin (4.8%) (Figure 4). An 
overview of obtained and expected results is 
reported in Appendix 7a. 
 
Enterococci identification (ID) 
As a mandatory component of the proficiency 
test, the participants were requested to identify 
the enterococci species. The eight strains 
included six E. faecalis strains ENT 9.1, 9.2, 
9.3, 9.6, 9.7 and 9.8) and two E. faecium (ENT 
9.4 and 9.5). The results were excellent as no 
deviations were observed in the 208 results 
uploaded. However Lab # 38 did not upload 
results for the ID of the eight test strains as they 
referred in the comments that they did not do 
the species ID and therefore did not upload an 
interpretation of the results obtained for 
quinopristin/dalfopristin for any of the test 
strains. 
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3.2.2 Staphylococci 
The results of the staphylococci trial showed 
that there were more than 25% deviations for 
two antimicrobial/strain combinations due to 
expected results being very close to the 
breakpoint. These combinations were: 
ciprofloxacin/ST 9.4 (58%) and quinopristin-
dalfopristin (SYN)/ ST 9.5 (56%).  
For the combination ciprofloxacin/ST 9.4, 24 
laboratories uploaded results and 58% of them 
(n=14) responded that the strain fell into the 
category of susceptible. This strain had an 
expected result of “R” due to an expected MIC 
value of 2 mg/L which is just above the 
breakpoint. From the fourteen laboratories 
having a deviation, ten laboratories observed 
an MIC value of 1mg/L (one step below the 
expected value), one laboratory had obtained a 
MIC value at 0.5 mg/L which is 2 steps below 
the expected value and one additional 
laboratory obtained a MIC value at <=0.25 
mg/L. 
Analysing the combination quinopristin 
dalfopristin/ST 9.5, we observed that a total of , 
18 laboratories uploaded results and 56% of 
them (n=10) responded that the strain was 
resistant. This strain had an expected MIC at 
1mg/L and was expected to be classified as 
susceptible. Nine of the laboratories reporting a 
deviation observed an MIC one step above the 
expected (at 2 mg/L), and one laboratory 
obtained an MIC two steps higher, at 4mg/L.  
The results obtained for the three described 
antimicrobial/strain combinations were omitted 
from the calculations in this report as they did 
not reflect the capacity of the laboratories to 
perform AST. 
Twenty-five laboratories representing the NRLs 
 
Figure 3. Enterococci trial: results deviating from the expected interpretation subdivided by tested strain 
 
 
























































                                                             
13 
for twenty-two MS and three non-MS countries 
have participated uploading results for the 
staphylococci trial. 
In general the results showed more variation in 
the methods, breakpoints and antimicrobials 
tested as testing of S. aureus is not included in 
the EU regulation and therefore does not have 
fixed test panels, even though the technical 
specifications from EFSA are giving guidance to 
the tests to perform AST on this species. 
However, for the test results submitted, 98.6% 
had correct interpretations.  
The results subdivided by strain showed that 
the obtained interpretations deviated from the 
expected ones slightly differently, with deviation 
percentages ranging from 0.3% for strain ST 
9.8 to 5.6% for strain ST 9.4 (Figure 5). In this 
case, the strain ST 9.4 showed a larger 
percentage of deviations in relation to past 
trials. By this we mean that particular strain was 
the internal control strain and therefore we can 
compare to historical results which show that 
the deviation percentage for this strain was 
below 5% since 2011. The relatively high 
deviation percentage was due to sixteen 
deviations (after excluding the results omitted 
for ciprofloxacin, for this strain) from which 
fourteen are related to MIC measured too high 
by five different laboratories and affecting 
results of several antimicrobials. 
Analysis of the staphylococci results sorted 
according to the tested antimicrobials showed 
that the highest percentages of deviation from 
expected interpretations were obtained in 
testing susceptibility to quinupristin-dalfopristin 
(SYN) (4.0%), followed by clindamycin (CLN) 
(3.7%) and erythromycin (ERY) (3%) (Figure 6). 
An overview of obtained and expected results is 
reported in Appendix 7b. 
 
Methicillin-resistant S. aureus 
this EQAS trial, we had six strain expected to 
be identified as methicillin resistant: ST: 9.1, 
9.2, 9.3, 9.4, 9.6 and 9.8. Strain ST 9.6 
harboured the mecC gene and all the remaining 
harboured the mecA gene.  
As for the EQAS on AST, all 25 participants on 
the staphylococci trial have submitted the 
methicillin results as these are a compulsory 
part the trial.  
Only one laboratory (Lab #2) had three 
deviations in this trial due to reporting strains 
ST 9.1, 9.2 and 9.8 as methicillin susceptible. 
All remaining results were correct. 
3.2.3 Escherichia coli  
In the E. coli trial we also observed one 
strain/antimicrobial combination which showed 
more than than 25% deviations. This was the 
case for meropenem EC 9.1. This strain EC 9.1 
was exactly the same as the one sent out in 
2014 as strain EC 8.7 and contains an OXA-48 
gene conferring reduced susceptibility to 
carbapenems, without causing high levels of 
cephalosporin resistance. Therefore, among the 
31 laboratories uploading results for this strain 
for the first panel, 14 (45.2%) of them 
considered this strain as susceptible in the first 
panel. However, not only the 17 participants 
that had found meropenem resistant but 
additional 7 participants (of the total of 24 
participants) tested this strain in the second 
panel. In this test there were four participants 
(17.4%) that did not detect the meropenem 
resistance. This way, the meropenem testing 
for both panels had an average deviation level 
of 33.3%. The deviation level for imipenem 
tests in the second panel was quite low, (at 9%) 
unlike in the previous EQAS. These issues 
might not reveal real problems in the AST 
methodology, but issues related to the low level 
of resistance of the particular strain, as the 
strain’s expected MIC for meropenem was 
relatively close to the breakpoint (0.5 mg/L) and 
most laboratories having this mistake had 
results just one step below the breakpoint at 
0.12 mg/L, however four laboratories had MIC 
levels at 0.06 mg/L and one at 0.03 mg/L which 
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could indicate loss of plasmid. There was also 
one laboratory were the interpretation was 
correct as “R”, even though the strain was 
tested at 0.12 mg/L for panel 1 as it probably 
was adjusted when finding a higher MIC value 
in panel 2, as well as several laboratories that 
performed panel 2 even though they did not 
observe meropenem resistance on the panel 1 
results. 
In general, the analysis of results from the E. 
coli trial showed that 98.6% of the results were 
interpreted correctly. Figure 2 shows the total 
percentage of deviations assigned to AST in 
this trial in relation to the previous trials which 
is a very similar levels in relation to 2014.  
Analysis of results deviating from expected 
interpretation subdivided by strain showed that 
the percentage of deviations ranged from none 
to 5.8% (Figure 7). The highest percentage of 
disagreement with expected results was 
obtained for EC 9.1 (Figure 7) and this is mainly 
due to the issues related to meropenem. An 
overview of obtained and expected results is 
reported in Appendix 7c. 
The results sorted according to antimicrobials 
showed that the highest percentages of 
deviation from expected interpretations were 
obtained in testing susceptibility to cefepime 
 
Figure 5. Staphylococci trial: results deviating from the expected interpretation subdivided by tested strain.  
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(5.1%) and meropenem (4.5%)(Figure 8). For 
cefepime the reason might be related mostly to 
cefepime expected MIC values close to the 
breakpoint in two of the strains EC 9.1 and 9.4 
and for meropenem the explanations are given 
above as most deviations are related to strain 
EC 9.1 (Figure 8). 
An overview of obtained and expected results is 
reported in Appendix 7c.  
 
Beta-lactamase-producing E. coli 
As for previous trials, the confirmation of beta-
lactamase production is a mandatory 
component of this EQAS.  
According to the protocol, which was based on 
the EFSA technical specifications the 
confirmatory test for ESBL production requires 
the testing of the second E. coli susceptibility 
testing panel. This panel is meant to be used to 
confirm the phenotype and perform a 
presumptive diagnosis of the type of gene(s) 
that might be present in the strains.  
For identification of ESBL phenotypes, one of 
the main concepts is synergy which is defined 
as a ≥ 3 twofold concentration decrease in an 
MIC for either cephalosporin agent tested in 
combination with clavulanic acid vs. its MIC 
when tested alone (CLSI M100 Table 2A; 
Enterobacteriaceae). Resistance to cefepime 
gives further indication of ESBL production. 
According to the most recent EFSA 
recommendations, confirmatory test for 
carbapenemase production requires the testing 
of meropenem (MER).  
Detection of AmpC-type beta-lactamase 
producing bacteria can be performed by testing 
the isolates for susceptibility to cefoxitin (FOX). 
Resistance to FOX could indicate the presence 
of an AmpC-type beta-lactamase, that may be 
verified by PCR and sequencing. 
The classification of the phenotypic results 
should be based on the most recent EFSA 
recommendations (EFSA, 2012), indicating as: 
• Presumptive ESBL: strains with positive 
synergy test, susceptible to cefoxitin 
and resistant to cefepime 
• Presumptive ESBL+pAmpC: -strains 
with positive or negative synergy test, 
resistant to cefoxitin and resistant to 
cefepime 
• Presumptive pAmpC phenotype: strains 
with negative synergy test resistant to 
cefoxitin and susceptible to cefepime 
• Presumptive carbapenemase 
phenotype: strain resistant to 
meropenem 
• Unusual phenotype: any other 
combinations 
In this EQAS, 31 laboratories have uploaded 
results from which 30 uploaded results for all 
eight strains and one did not upload a result for 
strain EC 9.6.  
Please note that for strain EC 9.4 no deviations 
were obtained as we adjusted the evaluation to 
accept both options “Presumptive pAmpC” and 
“presumptive ESBL+pAmpC” mixed phenotype 
obtained, even though this strain was an AmpC 
carrying CMY-2 and TEM-1B genes, but 
showing FEP resistance.  
Deviations from expected results were obtained 
as follows: 
Eight participants (Lab #17, #19 and #21, #23, 
#26 , #29, #40 and #42) did not identify EC 9.1 
as a carbapenemase producing strain as they 
did not find the carbapenemase resistance and 
classified it as: “No ESBL, AmpC- or 
carbapenemase. 
One participant (Lab #56) misclassified EC 9.3 
which was an ESBL carrying the CTX-M-1 gene
 as containing “No ESBL, AmpC- or 
carbapenemase”. Strain EC 9.6 did not harbour 
a resistant phenotype was misclassified as 
presumptive ESBL by Lab #33 and presumptive 
pAmpC by lab #39. This was not further 
explained but could be related to switch of 
trains or results as further results were found 
deviating for this strain.  
Regarding the EC 9.7 this strain had a mixed 
phenotype due to the CTX-M-1 and CMY-2 
genes and was expected to be classified as 
presumptive ESBL+pAmpC. Only one deviation 
was noted as Lab #30 considered this strain 
only to be presumptive ESBL. 
Finally, strain EC 9.8 was an ESBL strain 
harbouring TEM-52 and only one participant 
(Lab#19) had a deviation due to classifying it as 
presumptive ESBL+AmpC.  
3.3 Deviations by participating 
laboratory 
The figures 9, 10 and 11 illustrate the 
percentage of deviations for each participant 
laboratory for each of the trials. 
One out of 27 participants obtained a 
percentage of deviations from expected results 
higher than 5% for enterococci (Figure 9), one 
out of 25 participants had above 5% deviation 
in the staphylococci trial (Figure 10) and none 
out of the 31 participants had above 5% 
 
 
Figure 7 E. coli trial: results deviating from the expected interpretation subdivided by tested strain and 
antimicrobial susceptibility test method used  
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deviation in the E. coli trial (Figure 11). These 
results will be the focus of the next sections. 
 
3.3.1 Enterococci  
The largest number of deviations (9.2%) and 
was obtained by lab #42. This laboratory 
reported all eight enterococci strains as 
resistant to tigecycline as they found the MIC at 
either 0.5 or 1 mg/L which is either one or two 
steps above the breakpoint. The expected MIC 
for the strains was 0.12 and 0.25 mg/L and 
were all expected to be reported as susceptible. 
As the deviation for the strain 9.3 was omitted, 
due to the high percentage level for this strain 
for the remaining participants, the tigecyline 
issue caused seven deviations for this 
participant after omission. Additionally, this 
participant had one deviation on strain ENT 9.5 
for ampicillin. Follow-up on the issues showed 
that the tigecycline issue might be related to the 
sensitivity of this particular drug to oxygen and 
light which might have been related to the batch 
of plates and media used. As a follow up on this 
issue we have run some test at the EURL with 
the batches of EUVENC plates we managed to 
receive form the NRLs. We have received 28 
plates from four laboratories (including Lab#42) 
and representing two batches: B4255 (18 
plates) and B 4423A (10 plates). In the 
laboratory we performed the testing of all 
Enterococci from EQAS 2015 and the E. 
faecalis ATCC 29212 on all the combinations 
that were possible. Testing was performed 
using the same methodology in parallel and 
using the same Mueller Hinton broth from 
TREK (batch 656272). 
As a result we observed that for all the 
tigecycline tests the results would be falling 
between 0.06 and 0.25 and interpreted as 
susceptible. As the deviations observed were 
due to obtaining MIC values at 0.5 or 1mg/L 
and interpretating the strain as resistant, we 
could not see this in our tests, so we cannot 
confirm that there was an issue with the plates 
and we can only conclude that the observed 
deviations in the EQAS might be due to issues 
related to the methodology or the media used in 
the laboratories affected. Later on, in the 
troubleshooting performed by the participant of 
the Lab#42 a more concrete cause for the 
deviation was found as the panels were 
incubated for 48h, which does not comply with 
the standards. However, as reported to the 
EURL-AR this modification in the procedure 
had not been applied to any of the routine 
isoaltes, but only when processing the EQAS 
strains. 
 
We do, therefore recommend to look closely at 
this issues and follow up on enterococci 
showing unexpected resistance to this 
antimicrobial which should be considered as a 
rare event. 
 
The second laboratory having a percentage of 
deviation above 5% for was lab #12 at 7.1% 
which obtained four deviations for (ENT 9.1, 
9.2, 9.3 and 9.5) for ampicillin due to higher 
MIC than the expected. In the follow up the 
participant mentioned that VETMIC plates were 
used and they were close to expiration date, 
which could explain the issues observed. 
Furthermore, this laboratory did not provide 
data for all the twelve antimicrobials, as they 
were using VETMIC plates and testing only to 
seven of these for each strain, thus influencing 
the number of test results. It was also clarified 
that this laboratory is not providing data for 
enterococci monitoring to EFSA but only 
running the EQAS strains and some other from 
diagnostic sources. 
 
The third laboratory having more than 5% 
deviation was laboratory #19 that had five 
deviations leading to 5.7% and similarly to lab 
#42 the deviations were due to tigecycline 
tested with one step above the breakpoint and 
the expected MIC. 
 
For further information please consult the 
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overview in the Appendixes (App. 8a). 
 
In summary, 26 of the 27 participants in the 
enterococci trial achieved the acceptance level 
by having less than 5% of results deviating from 
the expected values (Figure 9). 
  
3.3.2 Staphylococci  
Analysis of laboratory performance of AST 
showed that one out of 25 participants obtained 
a percentage of deviations from expected 
results higher than 5.0% (Figure 10). 
Participant #29 was considered outlier due to 
the percentages of deviations obtained. This 
participant had 9.1% deviations corresponding 
to ten deviations (there were initially 12 
deviations but as two initial deviations were 
relating to strain/antimicrobial combinations 
omitted from the report these are not mentioned 
further). These deviations were related to the 
testing of three strains; ST 9.4 (six 
antimicrobials), ST 9.5 (two antimicrobials) and 
ST 9.6 (two antimicrobials). For most of the 
deviations higher MICs were obtained for the 
test strains than expected. After communication 
with the participant it was referred that the 
deviations were caused by Mueller Hinton broth 
that was not prepared according to the 
requirements. Furthermore, the participant 
reported that measures had been implemented 
to ensure performance of employees preparing 
media. 
In summary, 24 of 25 participants in the 
staphylococci trial achieved the acceptance 
level by having less than 5% of results deviating 
from the expected values and only one 
laboratory had a larger deviation percentage 
and was considered an outlier (Figure 10). 
Deviations from expected results obtained by 
each participant in the staphylococci trial are 
reported in Appendix 8b. 
 
 
3.3.3 Escherichia coli  
Analysis of laboratory performance of AST 
showed that none of the 31 participants 
obtained a percentage of deviations from 
expected results higher than 5% in the E. coli 
trial, being the highest deviation level at 4.5% 
and in this way all participants in the E. coli trial 
achieved the acceptance level by having less 
than 5% of results deviating from the expected 
values (Figure 12).  
 
3.4 Deviations from expected 
results for the reference strains 
The results for antimicrobial susceptibility 
testing of the reference strains have been 
evaluated according to the CLSI-established 
quality control (QC) ranges (App. 5). 
3.4.1 Enterococcus faecalis ATCC 29212 
In total 27 participants performed AST of E. 
faecalis ATCC 29212 by MIC determination. 
Three of the results for tigecycline were found 
outside of range due to obtained MICs one or 
two steps too high. This was the case for the 
results submitted by participant labs #2, #19 
and #42 which also had deviations in the results 
uploaded for the test strains showing the same 
trend.  
In summary, out of 299 tests performed by 27 
participants, 296 test results were found correct 
(Table 3). 
3.4.2 Staphylococcus aureus ATCC 29213 
Twenty-five participants performed AST of S. 
aureus ATCC 29213 by MIC determination 
towards a variable number of antimicrobials. In 
this EQAS only one deviations was obtained by 
Lab #37 by testing sulfamethoxazole one steps 
below the QC range (Table 4). In summary, out 
of 276 tests submitted, 275 were correct and 
one was deviating. 
3.4.3 Escherichia coli ATCC 25922 
Thirty-one participants performed AST of E. coli 
ATCC 25922 by MIC determination and  




Figure 9 Percentage of deviations from expected results obtained by each laboratory in the 
Enterococci trial. The laboratories were ranked by decreasing percentage of deviations from 
expected results in antimicrobial susceptibility testing. 
 
 
Figure 10 Percentage of deviations from expected results obtained by each laboratory in the 
Staphylococci trial. The laboratories were ranked by decreasing percentage of deviations from 
expected results in antimicrobial susceptibility testing. 
 
 
Figure 11. Percentage of deviations from expected results obtained by each laboratory in the 
Escherichia coli trial. The laboratories were ranked by decreasing percentage of deviations 
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uploaded data for the reference strain regarding  
the antimicrobials in the first panel for which 
there is a QC range available whereas only 27 
uploaded values for the second panel. One 
value for sulfamethoxazole was not reported 
correctly by lab #59 as “###” was reported 
instead of a valid MIC value. Four deviations 
were detected by the automatic system, 
however one was due to entering “###” instead 
of a valid MIC value and therefore cannot count 
as a deviation on the testing. The remaining 
three deviations were obtained for nalidixic acid 
tested one step above range (Lab#19), 
sulfamethoxazole tested one step above range 
(Lab #16) and trimethroprim tested one step 
below the QC range (Lab #60). For the 
antimicrobials tested in the second panel there 
were some laboratories that did not upload data 
for testing the reference strain on this panel. 
This was the case for Labs #22, #26, 37 and 
#60. Additionally and #21 uploaded partial data 
lacking cefotaxime and ceftazidime results 
however all results uploaded were found within 
range. 
 
In summary, out of 402 tests performed in the 
first panel, 398 were correct and in the second 
panel all 187 tests performed were found 
correct. 
 
For further information please consult App 6a, 
6b and 6c. 
  
Table 3. Antimicrobial susceptibility testing of 
Enterococcus faecalis ATCC 29212 by MIC 









Ampicillin  0/26 (0%) - - 
Chloramphenicol 0/27 (0%) - - 
Ciprofloxacin  0/24 (0%) - - 
Daptomycin 0/22 (0%) - - 
Erythromycin 0/27 (0%) - - 
Gentamicin 0/27 (0%) - - 
Linezolid 0/27 (0%) - - 
Quinu-dalfo-pristin  0/21 (0%) - - 
Teicoplanin 0/22 (0%) - - 
Tetracycline 0/27 (0%) - - 
Tigecycline 3/22 (14%) - 1 step (2) 2 steps (1) 
Vancomycin 0/27 (0%) - - 
 
Table 4. Antimicrobial susceptibility testing of 
Staphylococcus aureus ATCC 29213 by MIC 










Cefoxitin 0/23 (0%) - - 
Chloramphenicol 0/24 (0%) - - 
Ciprofloxacin 0/24 (0%) - - 
Clindamycin 0/24 (0%) - - 
Erythromycin 0/25 (0%) - - 
Gentamicin 0/24 (0%) - - 
Linezolid 0/20 (0%) - - 
Mupirocin No range - - 
Quinu-dalfo-pristin 0/19 (0%) - - 
Sulfisoxazole 1/20 (5%) 1 step - 
Sulfametoxazol + 
Trimethoprim 0/4 (0%) - - 
Tetracycline 0/25 (0%) - - 
Tiamulin No range - - 
Trimethoprim 0/24 (0%) - - 
Vancomycin 0/20 (0%) - - 
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4. Discussion 
4.1 General overview 
In general, the results were comparable to 
recent years and the overall deviation levels for 
AST in the three trials were just slightly lower 
for enterococci and staphylococci and slightly 
higher for E. coli with percentage of deviations 
ranging from 1.3% to 1.4%. (Figure 2). The 
results observed with the internal control strain, 
showed similar value for the enterococcus 
strain and higher deviation level for the 
staphylococcus strain and a smaller increase in 
the deviation level for the E. coli strain. The 
results for all three bacterial species and the 
deviation levels for these strains ranged from 
0.6% to 5.6% (Figure 2).  
It is important to consider that the number of 
EQAS participants changes slightly from year to 
year, which implies that comparisons among 
different EQAS iterations might be difficult to 
interpret. Furthermore, results from three 
laboratories from EU–affiliated countries non-
MS were included in this report.  
The network has now implemented the EU 
regulation and therefore the AST methodology 
has been harmonized among NRLs for testing 
E. coli and enterococci. This shows by having 
most laboratories uploading data for all 
antimicrobials in the panels. However, not all 
results are uploaded, denoting possibly that not 
all laboratories are yet able to deliver data for 
all antimicrobials. However, as staphylococci 










Ampicillin 1 0/31 (0%) - - 
Azithromycin 1 No range - - 
Cefotaxime 1 0/30 (0%) - - 
Ceftazidime 1 0/31 (0%) - - 
Chloramphenicol 1 0/31 (0%) - - 
Ciprofloxacin 1 0/31 (0%) - - 
Colistin 1 0/31 (0%) - - 
Gentamicin 1 0/31 (0%) - - 
Meropenem 1 0/31 (0%) - - 
Nalidixic acid 1 1/31 (3%) - 1 step 
Sulfamethoxazole 1 2/31 (6%) ####* 1 step 
Tetracycline 1 0/31 (0%) - - 
Tigecycline 1 0/31 (0%) - - 
Trimethoprim 1 1/31 (3%) 1 step - 
Cefepime 2 0/27 (0%) - - 
Cefotaxime 2 0/26 (0%) - - 
CTX/clav acid 2 No range - - 
Cefoxitin 2 0/27 (0%) - - 
Ceftazidime 2 0/26 (0%) - - 
CAZ/ clav acid 2 No range - - 
Ertapenem 2 0/27 (0%) - - 
Imipenem 2 0/27 (0%) - - 
Meropenem 2 0/27 (0%) - - 
Temocillin 2 No range - - 
• One participant wrote “####” into the response field, therefore obtaining a deviation, which cannot be considered a real mistake. 
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are not included in the regulation there are 
some discrepancies in the tests performed in 
relation to the EFSA recommended 
antimicrobials, between participants as they are 
using different panels for the testing. 
4.2 Enterococci  
The percentages of deviations observed ranged 
from 0.4% to 2.0% among the different test 
strains (Figure 3). These percentages are 
relatively similar to previous trials in the latest 
years.  
As mentioned previously, three participants 
submitted more than 5% deviating results 
(Figure 9). These participants have been 
contacted by the EURL-AR to perform 
troubleshooting to find the possible causes of 
issues in the performance and as problems 
have been detected regarding tigecycline the 
EURL also obtained panel from the possibly 
affected batches to compare. Results have 
been disseminated to the NRL network and 
further discussions on this subject will be 
included in the forthcoming EURL-AR 
Workshop. When comparing the 2015 results 
with 2014, the deviation level was actually 
decreased in total.  
The number of participants performing AST for 
enterococci with 100% agreement with the 
expected results was 16 (59%), which is only 
slightly fewer than last year.  
The results for the of the quality control strain E. 
faecalis ATCC 29212 was very good for the 27 
participants (Table 3). In summary, out of 299 
tests performed overall, 296 (98.9%) were 
within range and only three were deviating.  
Regarding the identification of the enterococci 
strains, the results were excellent with no 
deviations in the 208 tests performed. However 
one laboratory (Lab #38) did not upload species 
identification results.  
4.3 Staphylococci  
The deviation percentages observed among the 
results for the different test strains ranged from 
0.3% to 5.6% among the different test strains 
which is slightly higher than in previous trials 
(Figure 5). However, the number of participants 
performing AST with 100% agreement with the 
expected results was higher than in the past 
trials and consisted of 14 participants (56%). 
Identification of methicillin-resistant strains was 
in general very good as only one laboratory 
(Lab #2) obtained all the three deviations 
observed in this trial, meaning that the 
remaining 24 laboratories had 100% correct 
methicillin resistance detection, which includes 
both mecA and mecC. This also means that 
laboratories within the EURL-AR network in 
general correctly identify MRSA. The deviations 
obtained by Lab #2 are related to two false 
negatives and one false positive result. From a 
total of 200 submitted results 197 (98.5%) were 
correct. 
AST of the quality control strain S. aureus 
ATCC 29213 in MIC determination resulted in 
99.6% correct tests as from the 276 submitted 
test results only one was deviating (Table 4). 
Overall, this performance was quite satisfactory.  
 
4.4 Escherichia coli  
The percentages of results deviating from the 
expected interpretations varied from 0.3% to 
6.9% among the different test strains, with 
seven of the strains showing deviation 
percentages between 0% to 5.8% and mostly 
strain EC 8.7 had a high deviation percent due 
to the difficulties observed in detection of 
meropenem resistance in both test panels 
(Figure 7). For further detail in the deviations 
observed please consult Appendix 8c. 
None of the 31 participants had deviation 
percentages above the 5% acceptance level, 
which is remarkable (Figure 11).  
The number of participants performing AST with 
100% agreement with the expected results was 
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however not very high at 8 (25%). Again, as for 
the previous year, this is mainly due to the high 
number of deviations for meropenem results for 
strain EC 9.1. 
As the results show for the third time, the 
detection of OXA- type carbapenemases should 
be further improved as eight deviations were 
noticed in classifying the strain EC 9.1. 
Additionally, we consider there is still room for 
improvements in the performance and 
interpretation of ESBL and AmpC phenotypes 
as five deviations were found concerning both 
ESBL and AmpC phenotype classification. 
AST of the quality control strain E. coli ATCC 
25922 resulted in 99% correct tests for both the 
first panel and the second panel as from a total 
of 589 tests, 585 were correct and four 
deviating, from which only three were real 
deviations (Table 5). Overall, this performance 




In 2015, the number of laboratories not 
performing AST above the acceptation level 
(i.e. > 5% deviating results) was relatively low 
and consistent with the results obtained in 
previous EQAS trials. Three out of 27 
participants obtained a percentage of deviations 
from expected results above 5% for enterococci 
(Figure 9), one out of 25 participants had above 
5% deviation in the staphylococci trial and was 
considered an outlier (Figure 10) and none of 
the 31 participants were above the acceptation 
threshold in the E. coli trial (Figure 11).  
The laboratories outside the acceptable level 
have been contacted to assess individually the 
causes of inadequate AST performance and 
these individual contacts should be taken as an 
opportunity to perform troubleshooting and self-
evaluation and to discuss with the EURL-AR on 
how to improve the AST results in the future.  
The enterococci ID module did not reveal any 
methodological issues, but as one participant 
did not upload this parameter, the EURL-AR will 
follow up on the laboratory capacity of 
performing the ID.  
In this trial, few issues with the methicillin 
resistance results were reported and therefore 
EURL-AR will follow up on any needs regarding 
the implementation of the correct detection and 
confirmation methods in these laboratories. 
Major focus will again be given next year on the 
correctly identification of E. coli producing beta-
lactamases of the ESBL, AmpC and especially 
the OXA-48 phenotypes which are difficult to 
detect. Also as part of the testing of isolates 
coming from the selective isolation where a 
large number of suspect isolates need to 
undergo phenotypic screening and be selected 
for confirmatory testing these methods needs to 
be applied correctly. We strongly encourage 
participants having difficulties in identifying 
these phenotypes to perform a re-test of the 
test strains as a training exercise, and to 
contact the EURL-AR in case any discussion is 
needed.  
Furthermore, focus will be at the new important 
resistance mechanism discovered- plasmid 
mediated colistin resistance. 
Finally, the EURL-AR welcomes suggestions for 
improvement in future EQAS trials and invites 
the network to contribute with ideas for material 
to be disseminated in newsletters, alert for 
training needs on specific focus areas which 
may be of interest of the network and improve 
the knowledge and skills of the laboratories 
involved in the AMR monitoring. 
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Appendix 1- EURL-AR EQAS pre-notification 
EQAS 2015 FOR E. COLI, STAPHYLOCOCCI AND ENTEROCOCCI 
The EURL-AR announces the launch of another EQAS, thus providing the opportunity for proficiency 
testing which is considered an essential tool for the generation of reliable laboratory results of consistently 
good quality. 
This EQAS consists of antimicrobial susceptibility testing of eight E. coli isolates, eight staphylococci and 
eight enterococci isolates. Additionally, quality control (QC) strains E. coli ATCC 25922 (CCM 3954), E. 
faecalis ATCC 29212 (CCM 4224) and S. aureus ATCC 29213 (CCM 4223) (for MIC) will be distributed to 
new participants. 
This EQAS is specifically for NRL’s on antimicrobial resistance. Laboratories designated to be NRL-AR do 
not need to sign-up to participate but are automatically regarded as participants. You may contact the EQAS-
Coordinator if you wish to inform of changes in relation to your level of participation in previous years. The 
EURL-AR will be able to cover the expenses for one parcel, only, per EU Member State. Therefore, 
countries with more than one laboratory registered on the EURL-AR contact-list will be contacted directly to 
confirm which laboratory will be included for participation free of charge.  
The invitation to participate in the proficiency test is extended to additional participants from official NRLs 
and participants from laboratories which are involved in the network but are not designated NRLs (cost for 
participation will be 100 euro). 
TO AVOID DELAY IN SHIPPING THE ISOLATES TO YOUR LABORATORY 
The content of the parcel is “UN3373, Biological Substance Category B. Eight E. coli, eight staphylococci, 
eight enterococci and for new participants also the QC strains mentioned above. Please provide the EQAS 
coordinator with documents or other information that can simplify customs procedures (e.g. specific text that 
should be written on the proforma invoice). To avoid delays, we kindly ask you to send this information 
already at this stage.  
TIMELINE FOR RESULTS TO BE RETURNED TO THE NATIONAL FOOD INSTITUTE 
Shipment of isolates and protocol: The isolates will be shipped in June 2015. The protocol for this 
proficiency test will be available for download from the website (www.eurl-ar.eu).  
Submission of results: Results must be submitted to the National Food Institute no later than September, 4th, 
2015, via the password-protected website.  
Upon reaching the deadline, each participating laboratory is kindly asked to enter the password-protected 
website once again to download an automatically generated evaluation report. 
EQAS report: A report summarising and comparing results from all participants will be issued. In the report, 
laboratories will be presented coded, which ensures full anonymity. The EURL-AR and the EU Commission, 
only, will have access to un-coded results. The report will be publicly available. 
Next EQAS: The next EURL-AR EQAS that we will have is on antimicrobial susceptibility testing of 
Salmonella and Campylobacter and a new EQAS on isolation of ESBL and ampC –producing E.coli from 
samples which are both expected to be carried out in October, 2015. 





EU Community Reference Laboratory, Antimicrobial Resistance, Søltofts Plads, Building 221, DK-2800 Kgs. Lyngby, 
Denmark.  Phone: + 45 3588 6269, Fax: + 45 3588 6341, e-mail: licav@food.dtu.dk
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Appendix 2- List of participants 
Institute  Country E coli Ent Staph
Austrian Agency for Health and Food Safety Austria x x x 
Institute of Public Health Belgium x 
Nacional Diagnostic and Research Veterinary Institute Bulgaria x x x 
Croatian Veterinary Institut Croatia x x x 
Veterinary Services  Cyprus x 
State Veterinary Institute Praha Czech Republic x x x 
Danish Veterinary and Food Administration Denmark x x 
Estonian Veterinary and Food Laboratory Estonia x x x 
Finnish Food Safety Authority EVIRA Finland x x x 
Agence nationale de sécurité sanitaire ANSES - Fougères France x x 
Federal Institute for Risk Assessment  Germany x x x 
Veterinary Laboratory of Chalkis Greece x 
Central Agricultural Office Veterinary Diagnostic Directorate Hungary x x x 
University of Iceland Iceland x x x 
Central Veterinary Research Laboratory Ireland x x x 
Istituto Zooprofilattico Sperimentale delle Regioni Lazio e Toscana Italy x x x 
Institute of Food Safety, Animal Health and Enviroment "BIOR" Latvia x x x 
National Food and Veterinary Risk Assessment Institute Lithuania x x x 
Laboratoire national de Santé Luxembourgh x 
Public Health Laboratory Malta x x x 
Food and Consumer Product Safety Authority (VWA) Netherlands x x x 
Central Veterinary Institute of Wageningen UR Netherlands x x x 
Veterinærinstituttet Norway x x x 
National Veterinary Research Institute Poland x x x 
Laboratorio National de Investigacáo Veterinaria Portugal x x x 
Institute for Diagnosis and Animal Health Romania x x x 
State Veterinary and Food Institute  (SVFI) Slovakia  x x x 
National Veterinary Institute Slovenia x x x 
Laboratorio Central de Sanidad, Animal de Santa Fe  Spain x 
Laboratorio Central de Sanidad, Animal de Algete Spain x x 
VISAVET Health Surveillance Center, Complutense University Spain x x x 
Agencia Espanola de Seguridad Alimentria y Nutricion Spain x x 
National Veterinary Institute, SVA Sweden x x x 
Vetsuisse faculty Bern, Institute of veterinary bacteriology Switzerland x x x 
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Appendix 3a- Expected results for the enterococci trial (MIC- values and interpretations) 
Strain nr Species DAP TGC TEI AMP CHL CIP ERY GEN LZD SYN TET VAN 
EURL ENT 9.1 E. faecalis 2 0,25 <=0,5 1 8 1 >128 >1024 2 32 64 2 
EURL ENT 9.2 E. faecalis 1 0,25 <=0,5 1 128 32 >128 <=8 2 8 128 1 
EURL ENT 9.3 E. faecalis 1 0,25 <=0,5 1 128 1 >128 256 2 16 128 1 
EURL ENT 9.4 E. faecium 8 0,25 <=0,5 >64 8 4 >128 8 2 4 128 2 
EURL ENT 9.5 E. faecium 0,5 0,12 >128 4 8 0,5 2 <=8 2 4 64 >128 
EURL ENT 9.6 E. faecalis 2 0,25 <=0,5 1 8 1 >128 16 2 16 <=1 2 
EURL ENT 9.7 E. faecalis 1 0,25 <=0,5 1 128 1 >128 8 2 16 128 2 
EURL ENT 9.8 E. faecalis 4 0,25 <=0,5 1 8 1 <=1 16 2 8 <=1 4 
              
              Strain nr Species DAP TGC TEI AMP CHL CIP ERY GEN LZD SYN TET VAN 
EURL ENT 9.1 E. faecalis S S S S S S R R S NA R S 
EURL ENT 9.2 E. faecalis S S S S R R R S S NA R S 
EURL ENT 9.3 E. faecalis S S S S R S R R S NA R S 
EURL ENT 9.4 E. faecium R S S R S S R S S S R S 
EURL ENT 9.5 E. faecium S S R S S S S S S S R R 
EURL ENT 9.6 E. faecalis S S S S S S R S S NA S S 
EURL ENT 9.7 E. faecalis S S S S R S R S S NA R S 
EURL ENT 9.8 E. faecalis S S S S S S S S S NA S S 
  
  Resistant 
 NA Not applicable 
Abbreviations: DAP- daptomycin, TIG- tigecycline, TEI- teicoplanin, AMP-ampicillin, CHL-chloramphenicol, CIP- ciprofloxacin, ERY- erythromycin, GEN- 
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Appendix 3b- Expected results for the staphylococci trial (MIC- values and interpretations) 
Strain nr Species VAN SYN LZD MUP CLN CHL CIP ERY FOX GEN SMX SXT TET TIA TMP methicillin R 
EURL ST 9.1 S. aureus <=1 8 2 <=0.06 >256 8 0.25 >16 8 0.25 <=32 <=0.25 >32 >32 <=0.5 MRSA 
EURL ST 9.2 S. aureus <=1 2 2 <=0.06 4 8 0.12 0.25 8 0.25 <=32 <=0.25 >32 >32 >32 MRSA 
EURL ST 9.3 S. aureus <=1 2 2 <=0.06 8 8 8 0.25 8 0.5 <=32 0.5 >32 >32 >32 MRSA 
EURL ST 9.4 S. aureus <=1 <=0,5 2 <=0,06 0.12 8 2 0.25 8 >16 256 <=0.25 32 0.5 1 MRSA 
EURL ST 9.5 S. aureus <=1 1 2 <=0.06 0,5 8 0,25 0.5 4 0.5 <=32 <=0.25 0.5 >32 1 MSSA 
EURL ST 9.6 S. aureus <=1 <=0,5 4 <=0.06 0.25 8 0.5 0.5 8 0,25 <=4 <=0.25 0,5 1 1 MRSA 
EURL ST 9.7 S. aureus <=1 <=0.5 2 <=0,06 0.12 8 0.25 0.25 4 0.25 <=32 <=0.25 0.25 1 1 MSSA 
EURL ST 9.8 S. aureus <=1 8 2 <=0.06 >256 16 0.25 >16 8 0.5 <=32 0.5 >32 >32 >32 MRSA 
                  
                  Strain nr Species VAN SYN LZD MUP CLN CHL CIP ERY FOX GEN SMX SXT TET TIA TMP methicillin R 
EURL ST 9.1 S. aureus S R S S R S S R R S S S R R S MRSA 
EURL ST 9.2 S. aureus S R S S R S S S R S S S R R R MRSA 
EURL ST 9.3 S. aureus S R S S R S R S R S S S R R R MRSA 
EURL ST 9.4 S. aureus S S S S S S R S R R R S R S S MRSA 
EURL ST 9.5 S. aureus S S S S R S S S S S S S S R S MSSA 
EURL ST 9.6 S. aureus S S S S S S S S R S S S S S S MRSA 
EURL ST 9.7 S. aureus S S S S S S S S S S S S S S S MSSA 
EURL ST 9.8 S. aureus S R S S R S S R R S S S R R R MRSA 
  
  Resistant 
NA Not applicable 
Abbreviations:,  CHL-chloramphenicol, CIP- ciprofloxacin,  CLN- Clindamycin, ERY- erythromycin, FOX- cefoxitin, LZD- linezolid, MUP- mupirocin,  GEN- 
gentamicin, SYN- quinupristin-dalfopristin,, SMX- sulphametoxazole, SXT- sulphametoxazole + trimethroprim, TET- tetracycline, TIA- tiamulin, TMP- 








Appendix 3c- Expected results for the E. coli  trial (MIC- values and interpretations) 
Panel 1 
Strain nr  Species  MERO COL AMP AZI  TAZ  CHL  CIP  FOT  GEN  NAL  SMX  TET TMP  TGC 
EURL EC 9.1 E. coli  0,5  <=1 >64  >64  <=0.5 128  <=0.015 <=0.25  >32  1  >1024 >64 >32  <=0.25
EURL EC 9.2 E. coli  <=0.03 <=1 <=1  4  0.12  8  <=0.015 <=0.06  1  2  <=8  <=2 <=0.25 <=0.25
EURL EC 9.3 E. coli  <=0.03 <=1 >64  8  2  4  <=0.015 64  0.5  2  <=16  <=2 <=0.25 <=0.25
EURL EC 9.4 E. coli  <=0.03 <=1 >64  8  8  >128 0.5  8  1  >128 >1024 >32 >32  <=0.25
EURL EC 9.5 E. coli  <=0.03 <=1 >64  4  8  >128 2  2  1  128  >1024 64  <=0.25 <=0.25
EURL EC 9.6 E. coli  <=0.03 <=1 4  4  0.25  0.5  0.5  <=0.06  1  >128 16  4  <=0.25 <=0.25
EURL EC 9.7 E. coli  0.06  <=1 >64  8  16  8  >8  32  1  >128 >1024 >64 <=0.25 1 
EURL EC 9.8 E. coli  <=0,03 <=1 >64  8  4  32  <=0,015 4  1  2  >1024 2  0,5  <=0,25
Strain nr  Species  MERO COL AMP AZI  TAZ  CHL  CIP  FOT  GEN  NAL  SMX  TET TMP  TGC 
EURL EC 9.1 E. coli  R  S  R  R  S  R  S  S  R  S  R  R  R  S 
EURL EC 9.2 E. coli  S  S  S  S  S  S  S  S  S  S  S  S  S  S 
EURL EC 9.3 E. coli  S  S  R  S  R  S  S  R  S  S  S  S  S  S 
EURL EC 9.4 E. coli  S  S  R  S  R  R  R  R  S  R  R  R  R  S 
EURL EC 9.5 E. coli  S  S  R  S  R  R  R  R  S  R  R  R  S  S 
EURL EC 9.6 E. coli  S  S  S  S  S  S  R  S  S  R  S  S  S  S 
EURL EC 9.7 E. coli  S  S  R  S  R  S  R  R  S  R  R  R  S  S 








 Panel 2 
Strain nr  Species  MERO  FEP  FOX  TAZ  FOT  T/C  F/C  IMI  ETP  TRM  ESBL conclusion 
EURL EC 9.1 E. coli  0,5  0,12  4  <=0,25 <=0,25  <=0,12  0,12  1  0,5  128  Presumptive carbapenemase
EURL EC 9.2 E. coli  not ESC
EURL EC 9.3 E. coli  <=0,03  32  4  2  64  <=0,12  <=0,06  0,12  <=0,015 4  Presumptive ESBL
EURL EC 9.4 E. coli  <=0,03  0,25  32  8  8  8  8  0,25  0,03  4  Presumptive AMPC
EURL EC 9.5 E. coli  <=0,03  0,25  4  8  2  <=0,12  <=0,06  <=0,12  <=0,015 4  Presumptive ESBL
EURL EC 9.6 E. coli  not ESC
EURL EC 9.7 E. coli  <=0,03  8  32  16  32  8  4  0,25  0,03  8  Presumptive AMPC+ ESBL
EURL EC 9.8 E. coli  <=0,03  0,5  4  4  4  <=0,12  <=0,06  0,25  <=0,015 8  Presumptive ESBL
Strain nr  Species  MERO  FEP  FOX  TAZ  FOT  T/C  F/C  IMI  ETP  TRM 
EURL EC 9.1 E. coli  R  S  S  S  S  NA  NA  R  R  NA 
EURL EC 9.2 E. coli                          
EURL EC 9.3 E. coli  S  R  S  R  R  NA  NA  S  S  NA 
EURL EC 9.4 E. coli  S  R  R  R  R  NA  NA  S  S  NA 
EURL EC 9.5 E. coli  S  R  S  R  R  NA  NA  S  S  NA 
EURL EC 9.6 E. coli                          
EURL EC 9.7 E. coli  S  R  R  R  R  NA  NA  S  S  NA 























EURL-AR External Quality Assurance System (EQAS) 2015: 










Please find enclosed the bacterial strains for the EURL-AR EQAS 2015. Upon arrival to your 
laboratory, the strains should be stored dark and at 4°C for stabs, and dark and cool for freeze-
dried strains.  
 
On the EURL-AR-website (www.eurl-ar.eu) the following documents relevant for the EURL-
AR EQAS are available: 
- Protocol for E. coli, staphylococci and enterococci including test forms  
- Instructions for Opening and Reviving Lyophilised Cultures 
- Subculture and Maintenance of Quality Control Strains  
 
We ask you to examine the eight E. coli, enterococci and S. aureus strains that we send to you 
by performing antimicrobial susceptibility testing. In the protocol you can find detailed 
description of the procedures to follow. Additionally, you can find a description of the 
procedure to enter your results into the interactive web database. For accessing the database, 
you need this username and password: 
 
Your username: «Username» 
 
Your password: «Password» 
 
Please keep this document 
  Your username and password will not appear in other documents 
 
Results should be entered in the database no later than 4th September 2015. Please 
acknowledge receipt of this parcel immediately upon arrival (to licav@food.dtu.dk) and do not 
hesitate to contact me for further information. 
Yours sincerely, 
Lina Cavaco 
Technical University of Denmark 
National Food Institute 
Kemitorvet 
Building 204 
DK-2800 Kgs. Lyngby 
Denmark 
Tel +45 35 88 70 00 
Dir. +45 35 88 62 69 
Fax +45 35 88 63 41  
licav@food.dtu.dk 
www.food.dtu.dk 
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For antimicrobial susceptibility testing of Escherichia coli, enterococci and staphylococci 
 
 
1 INTRODUCTION  ................................................................................................................. 1 
2 OBJECTIVES  ....................................................................................................................... 2 
3 OUTLINE OF THE EC/ENT/STAPH EQAS 2015  ........................................................... 2 
Shipping, receipt and storage of strains  ............................................................................ 2 
Suggested procedure for reconstitution of the lyophilised reference strains  ................. 2 
Antimicrobial susceptibility testing  ................................................................................... 2 
4 REPORTING OF RESULTS AND EVALUATION  ......................................................... 6 
4.1 General recommendations for data upload  ........................................................... 6 
5 HOW TO ENTER RESULTS IN THE INTERACTIVE DATABASE  ........................... 7 
5.1 AST of E. coli, enterococci and staphylococci  ....................................................... 7 
 
1 INTRODUCTION 
The organisation and implementation of an External Quality Assurance System (EQAS) on 
antimicrobial susceptibility testing (AST) of E. coli, enterococci and staphylococci is among the 
tasks of the EU Reference Laboratory for Antimicrobial Resistance (EURL-AR). The EC/Ent/Staph 
EQAS 2015 will include AST of eight E. coli, eight enterococci and eight staphylococci strains and 
AST of reference strains E. coli ATCC 25922 (CCM 3954), E. faecalis ATCC 29212 (CCM 4224), 
and S. aureus ATCC 29213 (CCM 4223).  
The above-mentioned reference strains are included in the parcel only for new participants of the 
EQAS who did not receive them previously. The reference strains are original CERTIFIED cultures 
provided free of charge, and should be used for future internal quality control for antimicrobial 
susceptibility testing in your laboratory. The reference strains will not be included in the years to 
come. Therefore, please take proper care of these strains. Handle and maintain them as suggested in 
the manual ‘Subculture and Maintenance of QC Strains’ available on the EURL-AR website (see 
www.eurl-ar.eu).  
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Various aspects of the proficiency test scheme may from time to time be subcontracted. When 
subcontracting occurs it is placed with a competent subcontractor and the National Food Institute is 
responsible to the scheme participants for the subcontractor’s work.  
2 OBJECTIVES 
This EQAS aims to support laboratories to assess and, if necessary, to improve the quality of results 
obtained by AST of pathogens of food- and animal-origin, with special regard to E. coli, 
enterococci and staphylococci. Further objectives are to evaluate and improve the comparability of 
surveillance data on antimicrobial susceptibility of E. coli, enterococci and staphylococci reported 
to EFSA by different laboratories. 
3 OUTLINE OF THE EC/ENT/STAPH EQAS 2015 
Shipping, receipt and storage of strains 
In June 2015, the National Reference Laboratories for Antimicrobial Resistance (NRL-AR) will 
receive a parcel containing eight E. coli, eight enterococci and eight staphylococci strains from the 
National Food Institute. This parcel will also contain reference strains, but only for participants who 
did not receive them previously. All strains belong to UN3373, Biological substance, category B. 
Extended spectrum beta-lactamase (ESBL)-producing strains as well as carbapenemase-producing 
strains and methicillin resistant Staphylococcus aureus (MRSA) will be included in the selected 
material.  
The reference strains are shipped lyophilised, while the test strains are stab cultures. On arrival, the 
stab cultures must be subcultured, and all cultures should be adequately stored until testing. A 
suggested procedure for reconstitution of the lyophilised reference strains is presented below.  
Suggested procedure for reconstitution of the lyophilised reference strains  
Please refer to the document ‘Instructions for opening and reviving lyophilised cultures’ reported on 
the EURL-AR-website (see www.eurl-ar.eu). 
Antimicrobial susceptibility testing 
The strains should be tested for susceptibility to the antimicrobials listed in Tables 1, 2 and 3, using 
the method implemented in your laboratory for performing monitoring for EFSA and applying the 
interpretative criteria listed below.  
Participants should perform minimum inhibitory concentration (MIC) determination using the 
methods stated in the EC regulation EC 652/2013. For staphylococci MIC methods should be used 
as well, according to the EFSA recommendations and the antimicrobials to test are those stated 
under the EFSA technical specifications (see Table 3). For interpretation of the results, use the cut-
off values listed in Tables 1, 2, 3 and 4 in this document. These values (except where indicated) 
represent the current epidemiological cut-off values developed by EUCAST (www.eucast.org), and 
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allow categorisation of bacterial isolates into two categories: Resistant or susceptible. A 
categorisation as intermediate is not accepted.  
Participants will not be allowed to use disk diffusion as the current regulation and recommendations 
only focus on MIC testing. 
 
3.1.1 E. coli  
Table 1: Antimicrobials recommended for AST of Escherichia coli and interpretative criteria according to table 1 in EC 
regulation 652/2013 
 
Antimicrobials for E. coli MIC (µg/mL) R is > 
Ampicillin, AMP 8 
Azithromycin, AZI 16* 
Cefotaxime, FOT 0.25  
Ceftazidime, TAZ 0.5  
Chloramphenicol, CHL 16 
Ciprofloxacin, CIP 0.06  
Colistin, COL 2 
Gentamicin, GEN 2 
Meropenem, MERO 0.125 
Nalidixic acid, NAL 16 
Sulfamethoxazole, SMX 64 
Tetracycline, TET 8 
Tigecycline, TGC 1 
Trimethoprim, TMP 2 
* Tentative ECOFF established from EFSA data. 
 
Plasmid-mediated quinolone resistance  
When performing antimicrobial susceptibility testing of E. coli, the interpretative criteria listed in 
Table 1 for results obtained by MIC-determination should be able to detect plasmid mediated 
quinolone resistant test strains.  
Beta-lactam resistance 
Confirmatory tests for ESBL production are mandatory on all strains resistant to cefotaxime 
(FOT), ceftazidime (TAZ) or meropenem and should be performed by testing the second panel of 
antimicrobials (Table 2 in this document corresponding to Table 4 in EC regulation 652/2013). 
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Table 2: Antimicrobials recommended for additional AST of Escherichia coli resistant to cefotaxime, ceftazidime or 
meropenem and interpretative criteria according to table 4 in EC regulation 652/2013 
Antimicrobials for E. coli MIC (µg/mL) R is > 
Cefepime, FEP 0.125 
Cefotaxime, FOT 0.25 
Cefotaxime + clavulanic acid (F/C) Not applicable  
Cefoxitin, FOX 8 
Ceftazidime, TAZ 0.5 
Ceftazidime + clavulanic acid (T/C) Not applicable 
Ertapenem, ETP 0.06 
Imipenem, IMI 0.5 
Meropenem, MERO 0.125 
Temocillin, TRM Not available* 
*Where no interpretative criteria are available, we request the participants upload the MIC value 
obtained, and do not select an interpretation. 
Confirmatory test for ESBL production requires use of both cefotaxime (FOT) and ceftazidime 
(TAZ) alone and in combination with a β-lactamase inhibitor (clavulanic acid). Synergy is defined 
either as i) a ≥ 3 twofold concentration decrease in an MIC for either antimicrobial agent tested in 
combination with clavulanic acid vs. its MIC when tested alone (MIC FOT : FOT/CL or TAZ : 
TAZ/CL ratio ≥ 8) (CLSI M100 Table 2A; Enterobacteriaceae). The presence of synergy indicates 
ESBL production. Resistance to cefepime gives further indication of ESBL production, but is not 
essential. 
Confirmatory test for carbapenemase production requires the testing of meropenem (MERO).  
Detection of AmpC-type beta-lactamases can be performed by testing the bacterium for 
susceptibility to cefoxitin (FOX). Resistance to FOX could indicate the presence of an AmpC-type 
beta-lactamase, that may be verified by PCR and sequencing. 
The classification of the phenotypic results should be based on the most recent EFSA 
recommendations (EFSA 2012), indicating the strains as: 
• Presumptive ESBL: strains with positive synergy test, susceptible to cefoxitin and resistant 
to cefepime  
• Presumptive ESBL+pAmpC: strains with positive or negative synergy test, resistant to 
cefoxitin and resistant to cefepime 
• Presumptive pAmpC phenotype: strains with negative synergy test, resistant to cefoxitin and 
susceptible to cefepime 
• Presumptive carbapenemase phenotype: strain resistant to meropenem 
• Unusual phenotype: any other combinations 
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(However we recommend that strains which show synergy with clavulanic acid for at least one of 
the third generation cephalosporins, cefotaxime or ceftazidime, should be considered ESBL, 
independently of the cefepime result) 
 
3.1.2 Enterococci  
Table 3: Antimicrobials recommended for AST of Enterococcus spp. and interpretative criteria according to table 3 in 
EC regulation 652/2013. 
Antimicrobials for enterococci MIC (µg/mL) R is > 
MIC (µg/mL) 
R is > 
 E. faecium E. faecalis 
Ampicillin, AMP 4 4 
Chloramphenicol, CHL 32 32 
Ciprofloxacin, CIP 4 4 
Daptomycin, DAP 4 4 
Erythromycin, ERY 4 4 
Gentamicin, GEN 32 32 
Linezolid, LZD 4 4 
Quinupristin-dalfopristin (Synercid), SYN 4* Not applicable 
Teicoplanin, TEI 2 2 
Tetracycline, TET 4 4 
Tigecycline, TGC 0.25 0.25 
Vancomycin, VAN 4 4 
*DANMAP 2009 (www.danmap.org)  
 
Identification of the Enterococcus spp. 
Species identification of the Enterococci must be performed by the NRLs using in-house methods 
or adopting the protocol available on the EURL-AR website under: www.eurl-ar.eu/233-
protocols.htm.  
 
3.1.3 Staphylococci  
Eight staphylococci strains will be sent to be tested in the AST component of the EQAS 2015. 
Identification of MRSA 
Confirmation of mecA and/or mecC presence is mandatory in this EQAS. For this purpose, you 
are recommended to use the PCR method protocol recommended by the EURL-AR (www.eurl-
ar.eu/233-protocols.htm) and upload the result as ‘positive’ or ‘negative’. According to CLSI 
recommendations (M100, Table 2C), all MRSA should be regarded as resistant to all β-lactam 
antibiotics. 
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Table 4: Antimicrobials recommended for AST of Staphylococcus aureus and interpretative criteria according to EFSA 
technical specifications (EFSA 2012) 
Antimicrobials for S. aureus MIC (µg/mL) R is > 
Cefoxitin, FOX 4 
Chloramphenicol, CHL 16 
Ciprofloxacin, CIP 1 
Clindamycin, CLN 0.25 
Erythromycin, ERY 1 
Gentamicin, GEN 2 
Linezolid, LZD 4 
Mupirocin, MUP 1 
Quinupristin-dalfopristin (Synercid), SYN 1 
Sulfamethoxazole, SMX 128 
Sulfamethoxazole+Trimethoprim, SXT 0.5 
Tetracycline, TET 1 
Tiamulin, TIA 2 
Trimethoprim, TMP 2 
Vancomycin, VAN 2 
*CLSI M100 Table 2C 
 
4 REPORTING OF RESULTS AND EVALUATION 
Please write your results in the test forms, and enter your results into the interactive web database. 
In addition, we kindly ask you to report in the database the tested MIC range for the staphylococci 
tests, (for this organism, only, as it is not covered by the EC regulation on MIC testing). Finally, if 
you did not use the cut-off values recommended in the protocol for interpretation of 
Staphylococcus AST results, please report the breakpoints used in the database. 
 
4.1 General recommendations for data upload 
We recommend reading carefully the description reported in paragraph 5 before entering your 
results in the web database. Results must be submitted no later than September 4th 2015. After 
the deadline when all participants have uploaded results, you will be able to login to the database 
once again, and to view and print an automatically generated report evaluating your results. Results 
in agreement with the expected interpretation are categorised as ‘correct’, while results deviating 
from the expected interpretation are categorised as ‘incorrect’. 
If you experience difficulties in entering your results, please contact us directly.  
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All results will be summarized in a report which will be publicly available. The data in the report 
will be presented with laboratory codes. A laboratory code is known to the individual laboratory, 
whereas the complete list of laboratories and their codes is confidential and known only to the 
EURL-AR and the EU Commission. All conclusions will be public. 
If you have questions, please do not hesitate to contact the EQAS Coordinator: 
Susanne Karlsmose 
National Food Institute 
Technical University of Denmark 
Søltofts Plads 221, DK-2800 Lyngby 
Denmark 
Tel: +45 3588 6601 
Fax: +45 3588 6341 
E-mail: suska@food.dtu.dk 
 
5 HOW TO ENTER RESULTS IN THE INTERACTIVE DATABASE 
Please read carefully this paragraph before entering the web page. 
Remember that you need by your side the completed test forms and the breakpoint values you used.  
Enter the EURL-AR EQAS 2015 start web page (http://eurl-ar.food.dtu.dk), write your username 
and password in lower-cases and press enter. Your username and password are indicated in the 
letter following your strains. Do not hesitate to contact us if you experience problems with the 
login. 
You can browse back and forth by using the Home or back keys, but please remember to save your 
inputs before. 
5.1 AST of E. coli, enterococci and staphylococci 
Click on either “E. coli”, “enterococci” or “staphylococci” for input of test results based on the 
results you are going to upload.  
Click on "Start of Data Entry - Methods and Breakpoints” 
In the next page, you can navigate among fields with the Tab-key and the mouse.  
Complete the fields related to the method used for antimicrobial susceptibility testing and the brand 
of MIC trays, etc.  
Click on “save” and then go back using the tab “home” and enter another test page to upload results  
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In the data entry pages, enter the obtained values and the interpretation (R, resistant or S, 
susceptible) for each E. coli, enterococcus and staphylococcus strain. 
For E. coli strains, remember to report also the results for the ESBL detection tests. 
For S. aureus strains, remember to report also the results for presence/absence of methicillin 
resistance. 
If you did not test for susceptibility to a given antimicrobial, please leave the field empty. 
Click on “save“ and then go back using the tab “home” and enter another test page to upload 
results.  
When uploading data on the reference strains, please enter MIC values in µg/ml. Remember to use 
the operator keys to show symbols like “equal to”, etc. 
Click on “save“. 
Review the input pages by browsing through the pages and make corrections if necessary. 
Remember to save a page if you make corrections. If you press home a page without saving 
changes, you will see an error screen. In this case, click on “save“ to save your results, browse back 
to the page and then continue. 
Please complete the evaluation form. 
Before approving your input, please be sure that you have filled in all the relevant fields because 
YOU CAN ONLY APPROVE ONCE!  The approval blocks your data entry in the interactive 
database. 
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Name:       
 
Name of laboratory:       
 
Name of institute:       
 
City:       
 
Country:       
 
E-mail:       
 
Fax:       
 
 
Comments:       
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TEST FORMS METHODS - Enterococci 
Which method did you use for antimicrobial susceptibility testing of enterococci in this EQAS: 
  MIC – Microtitre    
  MIC – Agar dilution 
 Brand:                            
 
How many Enterococcus spp. isolates does your laboratory annually isolate:       
 
How many Enterococcus spp. isolates does your laboratory annually test for antimicrobial 
susceptibility by a MIC method:       
 
Which method was followed for the preparation of the inoculum (please describe) 
• Which standard was followed (TREK, CLSI…)       
• Which solvent was used for the preparation of the 0.5 McFarland solution (water, saline)       
• Please describe in detail how you prepared the dilution of the inoculum (including the volume in 
final MH-dilution and intended dilution level; e.g. diluted 1:1000 by adding 10µl of 0.5 
McFarland solution in 10ml MH broth, for an expected inoculum of 1*105 CFU/ml)       
 
Comments or additional information:       
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TEST FORMS METHODS - staphylococci 
Which method did you use for antimicrobial susceptibility testing of staphylococci in this EQAS: 
  MIC – Microtitre    
  MIC – Agar dilution 
 
 Brand:                            
How many Staphylococcus spp. isolates does your laboratory annually isolate:       
How many Staphylococcus spp. isolates does your laboratory annually test for antimicrobial 
susceptibility by a MIC method:       
 
Which method was followed for the preparation of the inoculum (please describe) 
• Which standard was followed (TREK, CLSI…)       
• Which solvent was used for the preparation of the 0.5 McFarland solution (water, saline)       
• Please describe in detail how you prepared the dilution of the inoculum (including the volume in 
final MH-dilution and intended dilution level; e.g. diluted 1:1000 by adding 10µl of 0.5 
McFarland solution in 10ml MH broth, for an expected inoculum of 1*105 CFU/ml)       
 
Comments or additional information:       
Antimicrobial  General info 
 











Cefoxitin, FOX        ≤             ≥       
Chloramphenicol, CHL       ≤             ≥       
Ciprofloxacin, CIP        ≤             ≥       
Clindamycin, CLN       ≤             ≥       
Erythromycin, ERY        ≤             ≥       
Gentamicin, GEN        ≤             ≥       
Linezolid, LZD       ≤             ≥       
Mupirocin, MUP       ≤             ≥       
Quin.-Dalf. (Synercid), SYN         ≤             ≥       
Sulfamethoxazole, SMX        ≤             ≥       
Sulfamethoxazole + Trimethoprim SXT       ≤             ≥       
Tetracycline, TET        ≤             ≥       
Tiamulin, (TIA)       ≤             ≥       
Trimethoprim, TMP        ≤             ≥       
Vancomycin, VAN       ≤             ≥       
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TEST FORMS METHODS – E. coli       
 
Which method did you use for antimicrobial susceptibility testing of E. coli in this EQAS: 
  MIC – Microtitre    
  MIC – Agar dilution 
 
 Brand:                            
 
 Incubation conditions:      °C/     h 
 
How many E. coli isolates does your laboratory annually isolate:       
 
How many E. coli isolates does your laboratory annually test for antimicrobial susceptibility by a 
MIC method:       
 
Which method was followed for the preparation of the inoculum (please describe) 
• Which standard was followed (TREK, CLSI…)       
• Which solvent was used for the preparation of the 0.5 McFarland solution (water, saline)       
• Please describe in detail how you prepared the dilution of the inoculum (including the volume in 
final MH-dilution and intended dilution level; e.g. diluted 1:1000 by adding 10µl of 0.5 
McFarland solution in 10ml MH broth, for an expected inoculum of 1*105 CFU/ml)       
 
 
Comments or additional information:       
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TEST FORM - Enterococci                                                            
 
Strain Antimicrobial  Results and interpretation 
≤ 
> 







 E. faecium 
 
 E. faecalis 
Ampicillin AMP                    
Chloramphenicol, CHL                   
Ciprofloxacin, CIP                   
Daptomycin, DAP                    
Erythromycin, ERY                    
Gentamicin, GEN                    
Linezolid, LZD                    
Quin.-Dalf. (Synercid), SYN                     
Teicoplanin, TEI                   
Tetracycline, TET                    
Tigecycline, TGC                   
Vancomycin, VAN                    
 
Strain Antimicrobial  Results and interpretation 
≤ 
> 







 E. faecium 
 
 E. faecalis 
Ampicillin AMP                    
Chloramphenicol, CHL                   
Ciprofloxacin, CIP                   
Daptomycin, DAP                    
Erythromycin, ERY                    
Gentamicin, GEN                    
Linezolid, LZD                    
Quin.-Dalf. (Synercid), SYN                     
Teicoplanin, TEI                   
Tetracycline, TET                    
Tigecycline, TGC                   
Vancomycin, VAN                    
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TEST FORM - Enterococci                                                          
 






Ampicillin, AMP        
Chloramphenicol, CHL          
Ciprofloxacin, CIP          
Daptomycin, DAP       
Erythromycin, ERY        
Gentamicin, GEN        
Linezolid, LZD        
Quinupristin-Dalfopristin (Synercid), SYN       
Teicoplanin, TEI       
Tetracycline, TET        
Tigecycline, TIG       
Vancomycin, VAN        
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TEST FORMS - Staphylococci  
 
Strain Antimicrobial  Results and interpretation 
≤ 
> 
MIC-value (μg/ml) S / R 
S. aureus 
 
EURL ST 9.X 
Cefoxitin, FOX                   
Chloramphenicol, CHL                   
Ciprofloxacin, CIP                    
Clindamycin, CLN                   
Erythromycin, ERY                    
Gentamicin, GEN                    
Linezolid, LZD                   
Mupirocin, MUP                   
Quino-dalfopristin (Synercid), SYN                   
Sulfamethoxazole, SMX                    
Sulfamethoxazole+Trimethoprim, SXT                   
Tetracycline, TET                    
Tiamulin, TIA                   
Trimethoprim, TMP                    
Vancomycin, VAN                   
 
 Methicillin resistance (MRSA)  Positive             Negative 
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TEST FORM - Staphylococci                                                         
 






Cefoxitin, FOX       
Chloramphenicol, CHL         
Ciprofloxacin, CIP         
Clindamycin, CLN       
Erythromycin, ERY        
Gentamicin, GEN        
Linezolid, LZD       
Mupirocin, MUP       
Quino-dalfo (Synercid), SYN       
Sulfamethoxazole, SMX        
Sulfamethoxazole+ Trimethoprim , SXT       
Tetracycline, TET        
Tiamulin, TIA       
Trimethoprim, TMP        
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TEST FORM – E. coli 
 
Strain Antimicrobial  Results and interpretation 
≤ 
> 
MIC-value (μg/ml) S / R 
E. coli 
EURL EC 9.X 
Ampicillin, AMP                         
Azithromycin, AZT                   
Cefotaxime, FOT                    
Ceftazidime, TAZ                    
Chloramphenicol, CHL                    
Ciprofloxacin CIP                         
Colistin, COL                   
Gentamicin, GEN                    
Meropenem, MERO                   
Nalidixic acid, NAL                    
Sulfamethoxazole, SMX                    
Tetracycline, TET                    
Tigecycline, TGC                   
Trimethoprim, TMP                    
 
All strains resistant to cefotaxime (FOT), ceftazidime (TAZ) or meropenem (MERO) should be 
included for testing in the second panel confirmatory tests for ESBL or carbapenemase production. 
See further description of confirmatory tests in the protocol section ‘3.1.1E. coli’.                                                   
 
Strain Antimicrobial  Results and interpretation 
≤ 
> 
MIC-value (μg/ml) S / R 
E. coli 
EURL EC 9.X 
Cefepime, FEP                   
Cefotaxime, FOT                    
Cefotaxime + clavulanic acid (F/C)                   
Cefoxitin, FOX                   
Ceftazidime, TAZ                   
Ceftazidime+ clavulanic acid (T/C)                   
Ertapenem, ETP                   
Imipenem, IMI                   
Meropenem, MERO                   
Temocillin, TRM                   
 Presumptive ESBL 
 Presumptive ESBL+ pAmpC 
 Presumptive pAmpC 
 Presumptive carbapenemase 
 
 Unusual phenotype 
 No ESBL, AmpC- or carbapenemase 
 
Comments (include optional genotype or other results):       
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TEST FORM – E. coli                                                           
 










Ampicillin, AMP        
Azithromycin, AZT       
Cefotaxime, FOT       
Ceftazidime, TAZ       
Chloramphenicol, CHL       
Ciprofloxacin, CIP       
Colistin, COL       
Gentamicin, GEN       
Meropenem, MERO       
Nalidixic acid, NAL       
Sulfamethoxazole, SMX       
Tetracycline, TET       
Tigecycline, TGC       
Trimethoprim, TMP       
2nd panel Cefepime, FEP       
Cefotaxime, FOT        
Cefotaxime, + clavulanic acid (F/C)       
Cefoxitin, FOX       
Ceftazidime, TAZ       
Ceftazidime + clavulanic acid (T/C)       
Ertapenem, ETP       
Imipenem, IMI       
Meropenem, MERO       
Temocillin, TRM       
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Instructions adjusted from Czech Collection of Microorganisms (CCM) document ’Instructions for 
Opening and Reviving of Freeze-Dried Bacteria and Fungi’ available on http://www.sci.muni.cz.  
Lyophilised cultures are supplied in vacuum-sealed ampoules. Care should be taken in opening the 
ampoule. All instructions given below should be followed closely to ensure the safety of the person 
who opens the ampoule and to prevent contamination of the culture. 
a. Check the number of the culture on the label inside the ampoule 
b. Make a file cut on the ampoule near the middle of the plug (see Figure 1) 
c. Disinfect the ampoule with alcohol-dampened gauze or alcohol-dampened cotton wool from 
just below the plug to the pointed end 
d. Apply a red-hot glass rod to the file cut to crack the glass and allow air to enter slowly into 
the ampoule 
e. Remove the pointed end of the ampoule into disinfectant 
f. Add about 0.3 ml appropriate broth to the dried suspension using a sterile Pasteur pipette 
and mix carefully to avoid creating aerosols. Transfer the contents to one or more suitable 
solid and /or liquid media 
g. Incubate the inoculated medium at appropriate conditions for several days 
h. Autoclave or disinfect effectively the used Pasteur pipette, the plug and all the remains of 
the original ampoule before discarding 
Notes:  
 Cultures should be grown on media and under conditions as recommended in the CCM 
catalogue (see http://www.sci.muni.cz) 
 Cultures may need at least one subculturing before they can be optimally used in experiments 








Figure 1: from CCM document ’Instructions for Opening 
and Reviving of Freeze-Dried Bacteria and Fungi’ available 
on http://www.sci.muni.cz 
Instructions for Opening and Reviving Lyophilised Cultures                                                         G00-06-001/01.12.2014 
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SUBCULTURE AND MAINTENANCE OF    
QUALITY CONTROL STRAINS 
1.1 Purpose 
Improper storage and repeated subculturing of bacteria can produce alterations in antimicrobial 
susceptibility test results. The Clinical and Laboratory Standards Institute (CLSI, formerly NCCLS) 
has published a guideline for Quality Control (QC) stock culture maintenance to ensure consistent 
antimicrobial susceptibility test results. 
1.2 References 
M100-S24, January 2014 (Performance Standards for Antimicrobial Susceptibility Testing) 
M7-A9, January 2012 (Methods for Dilution Antimicrobial Susceptibility Test for Bacteria That 
Grow Aerobically; Approved Standard) 
1.3 Definition of Terms 
Reference Culture: A reference culture is a microorganism preparation that is acquired from a 
culture type collection.  
Reference Stock Culture: A reference stock culture is a microorganism preparation that is derived 
from a reference culture. Guidelines and standards outline how reference stock cultures must be 
processed and stored.  
Working Stock Cultures: A working stock culture is growth derived from a reference stock culture. 
Guidelines and standards outline how working stock cultures must be processed and how often they 
can be subcultured.  
Subcultures (Passages): A subculture is simply the transfer of established microorganism growth on 
media to fresh media. The subsequent growth on the fresh media constitutes a subculture or 
passage. Growing a reference culture or reference stock culture from its preserved status (frozen or 
lyophilized) is not a subculture. The preserved microorganism is not in a stage of established 
growth until it is thawed or hydrated and grown for the first time 
1.4 Impor tant Considerations 
 Do not use disc diffusion strains for MIC determination. 
 Obtain QC strains from a reliable source such as ATCC 
 CLSI requires that QC be performed either on the same day or weekly (only after 30 day QC 
validation) 
 Any changes in materials or procedure must be validated with QC before implemented 
 For example: Agar and broth methods may give different QC ranges for drugs such as 
glycopeptides, aminoglycosides and macrolides 
 Periodically perform colony counts to check the inoculum preparation procedure 
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Page 1 of 4 
 
 






 Ideally, test values should be in the middle of the acceptable range 
 Graphing QC data points over time can help identify changes in data helpful for 
troubleshooting problems 
1.5 Storage of Reference Strains 
Preparation of stock cultures 
 Use a suitable stabilizer such as 50% fetal calf serum in broth, 10-15% glycerol in tryptic 
soy broth, defibrinated sheep blood or skim milk to prepare multiple aliquots. 
 Store at -20°C, -70°C or liquid nitrogen. (Alternatively, freeze dry.) 
 Before using rejuvenated strains for QC, subculture to check for purity and viability. 
Working cultures 
 Set up on agar slants with appropriate medium, store at 4-8°C and subculture weekly. 
 Replace the working strain with a stock culture at least monthly. 
 If a change in the organisms inherent susceptibility occurs, obtain a fresh stock culture or a 
new strain from a reference culture collection e.g. ATCC. 
1.6 Frequency of Testing 
Weekly vs. daily testing  
Weekly testing is possible if the lab can demonstrate satisfactory performance with daily testing as 
follows: 
 Documentation showing reference strain results from 30 consecutive test days were within 
the acceptable range. 
 For each antimicrobial/organism combination, no more than 3 out of 30 MIC values may be 
outside the acceptable range. 
When the above are fulfilled, each quality control strain may be tested once a week and whenever 
any reagent component is changed. 
Corrective Actions  
If an MIC is outside the range in weekly testing, corrective action is required as follows: 
 Repeat the test if there is an obvious error e.g. wrong strain or incubation conditions used 
 If there is no obvious error, return to daily control testing 
The problem is considered resolved only after the reference strain is tested for 5 consecutive days 
and each drug/organism result is within specification on each day. 
If the problem cannot be resolved, continue daily testing until the errors are identified. 
Repeat the 30 days validation before resuming weekly testing.  
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DAILY MIC QC CHART 
 
  Reference: CLSI M7-A9, page 46 
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Reference: CLSI M7-A7, page 40 Reference: CLSI M7-A9, page 47 
Subculture and Maintenance of QC strains                                                                                                                     G00-06-001/01.12.2014  
Page 4 of 4 
 
 
Appendix 5 Page 1 of 2 
Appendix 5- Quality control ranges for ATCC QC strains 
 
Escherichia coli ATCC 25922 
Panel  Antimicrobial  Min. Max 
1 
Ampicillin AMP 2 8 
Azithromycin AZI   
Cefotaxime FOT 0.03 0.12 
Ceftazidime TAZ 0.06 0.5 
Chloramphenicol CHL 2 8 
Ciprofloxacin CIP 0.004 0.015 
Colistin COL 0.25 2 
Gentamicin GEN 0.25 1 
Meropenem MER 0.008 0.06 
Nalidixic acid NAL 1 4 
Sulfamethoxazole SMX 8 32 
Tetracycline TET 0.5 2 
Tigecycline TGC 0.03 0.25 
Trimethoprim TMP 0.5 2 
     
2 
Cefepime FEP 0.015 0.12 
Cefotaxime/clavulanic acid F/C   
Cefotaxime FOT 0.03 0.12 
Cefoxitin FOX 2 8 
Ceftazidime TAZ 0.06 0.5 
Ceftazidime/clavulanic acid T/C   
Ertapenem ETP 0.004 0.015 
Imipenem IMI 0.06 0.25 
Meropenem MER 0.008 0.06 
Temocillin TRM   
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Enterococcus faecalis ATCC 29212 
 
Antimicrobial  min max 
Daptomycin DAP 1 4 
Linezolid LZD 1 4 
Chloramphenicol CHL 4 16 
Ciprofloxacin CIP 0.25 2 
Gentamicin GEN 4 16 
Erythromycin ERY 1 4 
Teicoplanin TEI 0.25 1 
Tetracycline TET 8 32 
Tigecycline TGC 0.03 0.12 
Vancomycin VAN 1 4 
Ampicillin AMP 0.5 2 
Quinopristin_Dalfo SYN 2 8 
  
Staphylococcus aureus ATCC 29213 
 
Antimicrobial  min max 
Cefoxitin FOX 1 4 
Chloramphenicol CHL 2 16 
Ciprofloxacin CIP 0.12 0.5 
Clindamycin CLN 0.06 0.25 
Erythromycin ERY 0.25 1 
Gentamicin GEN 0.12 1 
Linezolid LZD 1 4 
Mupirocin MUP   
Quinopristin_Dalfo SYN 0.25 1 
Sulfamethoxazole SMX 32 128 
Sulfamethoxazole-Trimethoprim SXT 0 0.5 
Tetracycline TET 0.12 1 
Tiamulin TIA   
Trimethoprim TMP 1 4 








Appendix 6a- Test results from reference strain Enterococcus faecalis ATCC 29212 
LAB ANTIMICROBIAL OPER VALUE MIN_VALUE MAX_VALUE SCORE 
2 Ampicillin = 1 0,5 2 1 
2 Chloramphenicol = 8 4 16 1 
2 Ciprofloxacin = 0,5 0,25 2 1 
2 Daptomycin = 2 1 4 1 
2 Erythromycin <= 1 1 4 1 
2 Linezolid = 2 1 4 1 
2 Quinopristin-dalfopristin (Synercid) = 8 2 8 1 
2 Teicoplanin <= 0,5 0,25 1 1 
2 Tetracycline = 32 8 32 1 
2 Tigecycline = 0,5 0,03 0,125 0 
2 Vancomycin = 4 1 4 1 
2 Gentamicin <= 8 4 16 1 
9 Ampicillin = 1 0,5 2 1 
9 Ciprofloxacin = 0,5 0,25 2 1 
9 Daptomycin = 2 1 4 1 
9 Erythromycin = 2 1 4 1 
9 Gentamicin <= 8 4 16 1 
9 Linezolid = 2 1 4 1 
9 Quinopristin-dalfopristin (Synercid) = 8 2 8 1 
9 Tetracycline = 16 8 32 1 
9 Tigecycline = 0,06 0,03 0,125 1 
9 Vancomycin = 2 1 4 1 
9 Chloramphenicol = 8 4 16 1 
9 Teicoplanin <= 0,5 0,25 1 1 
11 Ampicillin <= 0,5 0,5 2 1 
11 Chloramphenicol <= 4 4 16 1 
11 Ciprofloxacin = 1 0,25 2 1 
11 Daptomycin = 2 1 4 1 
11 Erythromycin = 2 1 4 1 
11 Linezolid = 1 1 4 1 
11 Quinopristin-dalfopristin (Synercid) = 2 2 8 1 
11 Tetracycline = 8 8 32 1 
11 Tigecycline <= 0,03 0,03 0,125 1 
11 Vancomycin = 2 1 4 1 
11 Gentamicin <= 8 4 16 1 
12 Ampicillin = 2 0,5 2 1 
12 Gentamicin = 8 4 16 1 
12 Linezolid = 2 1 4 1 
12 Tetracycline = 32 8 32 1 
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LAB ANTIMICROBIAL OPER VALUE MIN_VALUE MAX_VALUE SCORE 
12 Chloramphenicol = 4 4 16 1 
12 Vancomycin = 2 1 4 1 
12 Erythromycin = 4 1 4 1 
16 Ampicillin = 2 0,5 2 1 
16 Chloramphenicol = 8 4 16 1 
16 Ciprofloxacin = 1 0,25 2 1 
16 Daptomycin = 2 1 4 1 
16 Linezolid = 2 1 4 1 
16 Quinopristin-dalfopristin (Synercid) = 8 2 8 1 
16 Teicoplanin <= 0,5 0,25 1 1 
16 Tetracycline = 32 8 32 1 
16 Tigecycline = 0,12 0,03 0,125 1 
16 Vancomycin = 4 1 4 1 
16 Gentamicin = 16 4 16 1 
16 Erythromycin = 2 1 4 1 
17 Ampicillin = 1 0,5 2 1 
17 Daptomycin = 2 1 4 1 
17 Erythromycin = 2 1 4 1 
17 Gentamicin <= 8 4 16 1 
17 Linezolid = 2 1 4 1 
17 Quinopristin-dalfopristin (Synercid) = 4 2 8 1 
17 Teicoplanin <= 0,5 0,25 1 1 
17 Tigecycline = 0,12 0,03 0,125 1 
17 Vancomycin = 2 1 4 1 
17 Chloramphenicol = 8 4 16 1 
17 Tetracycline = 32 8 32 1 
17 Ciprofloxacin = 0,5 0,25 2 1 
19 Chloramphenicol = 8 4 16 1 
19 Ciprofloxacin = 0,5 0,25 2 1 
19 Daptomycin = 2 1 4 1 
19 Erythromycin = 2 1 4 1 
19 Linezolid = 2 1 4 1 
19 Quinopristin-dalfopristin (Synercid) = 8 2 8 1 
19 Teicoplanin <= 0,5 0,25 1 1 
19 Tigecycline = 0,25 0,03 0,125 0 
19 Vancomycin = 2 1 4 1 
19 Gentamicin = 16 4 16 1 
19 Ampicillin = 1 0,5 2 1 
19 Tetracycline = 32 8 32 1 
20 Ampicillin = 1 0,5 2 1 
20 Chloramphenicol = 8 4 16 1 
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LAB ANTIMICROBIAL OPER VALUE MIN_VALUE MAX_VALUE SCORE 
20 Ciprofloxacin = 1 0,25 2 1 
20 Erythromycin = 2 1 4 1 
20 Gentamicin = 16 4 16 1 
20 Quinopristin-dalfopristin (Synercid) = 8 2 8 1 
20 Teicoplanin <= 0,5 0,25 1 1 
20 Tigecycline = 0,12 0,03 0,125 1 
20 Vancomycin = 4 1 4 1 
20 Daptomycin = 4 1 4 1 
20 Tetracycline = 32 8 32 1 
20 Linezolid = 2 1 4 1 
21 Chloramphenicol = 4 4 16 1 
21 Ciprofloxacin = 0,5 0,25 2 1 
21 Erythromycin = 1 1 4 1 
21 Linezolid = 1 1 4 1 
21 Quinopristin-dalfopristin (Synercid) > 4 2 8 1 
21 Vancomycin = 1 1 4 1 
21 Tetracycline > 16 8 32 1 
21 Gentamicin = 8 4 16 1 
22 Ampicillin = 1 0,5 2 1 
22 Chloramphenicol = 8 4 16 1 
22 Ciprofloxacin = 0,5 0,25 2 1 
22 Daptomycin = 1 1 4 1 
22 Gentamicin = 16 4 16 1 
22 Linezolid = 2 1 4 1 
22 Teicoplanin <= 0,5 0,25 1 1 
22 Tetracycline = 32 8 32 1 
22 Vancomycin = 2 1 4 1 
22 Erythromycin = 2 1 4 1 
23 Ampicillin = 1 0,5 2 1 
23 Chloramphenicol = 8 4 16 1 
23 Ciprofloxacin = 0,25 0,25 2 1 
23 Erythromycin = 2 1 4 1 
23 Gentamicin <= 8 4 16 1 
23 Linezolid = 1 1 4 1 
23 Quinopristin-dalfopristin (Synercid) = 2 2 8 1 
23 Teicoplanin <= 0,5 0,25 1 1 
23 Tigecycline = 0,06 0,03 0,125 1 
23 Vancomycin = 2 1 4 1 
23 Tetracycline = 8 8 32 1 
23 Daptomycin = 1 1 4 1 
25 Ampicillin = 1 0,5 2 1 
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LAB ANTIMICROBIAL OPER VALUE MIN_VALUE MAX_VALUE SCORE 
25 Chloramphenicol = 8 4 16 1 
25 Ciprofloxacin = 1 0,25 2 1 
25 Erythromycin = 2 1 4 1 
25 Gentamicin = 16 4 16 1 
25 Quinopristin-dalfopristin (Synercid) = 8 2 8 1 
25 Teicoplanin <= 0,5 0,25 1 1 
25 Tigecycline = 0,12 0,03 0,125 1 
25 Vancomycin = 4 1 4 1 
25 Daptomycin = 2 1 4 1 
25 Tetracycline = 32 8 32 1 
25 Linezolid = 2 1 4 1 
26 Ampicillin <= 0,5 0,5 2 1 
26 Chloramphenicol = 8 4 16 1 
26 Ciprofloxacin = 1 0,25 2 1 
26 Erythromycin = 2 1 4 1 
26 Gentamicin <= 8 4 16 1 
26 Teicoplanin <= 0,5 0,25 1 1 
26 Tetracycline = 16 8 32 1 
26 Tigecycline = 0,12 0,03 0,125 1 
26 Vancomycin = 4 1 4 1 
26 Linezolid = 2 1 4 1 
26 Daptomycin = 1 1 4 1 
29 Ampicillin = 1 0,5 2 1 
29 Ciprofloxacin = 0,5 0,25 2 1 
29 Daptomycin = 1 1 4 1 
29 Erythromycin = 4 1 4 1 
29 Gentamicin = 8 4 16 1 
29 Quinopristin-dalfopristin (Synercid) = 8 2 8 1 
29 Teicoplanin <= 0,5 0,25 1 1 
29 Tetracycline = 32 8 32 1 
29 Vancomycin = 2 1 4 1 
29 Linezolid = 2 1 4 1 
29 Chloramphenicol = 8 4 16 1 
29 Tigecycline = 0,12 0,03 0,125 1 
30 Ampicillin <= 0,5 0,5 2 1 
30 Chloramphenicol <= 4 4 16 1 
30 Ciprofloxacin = 1 0,25 2 1 
30 Erythromycin = 2 1 4 1 
30 Gentamicin <= 8 4 16 1 
30 Linezolid = 2 1 4 1 
30 Quinopristin-dalfopristin (Synercid) = 4 2 8 1 
  
Appendix 6a, Page 5 of 8 
 
 
LAB ANTIMICROBIAL OPER VALUE MIN_VALUE MAX_VALUE SCORE 
30 Tigecycline = 0,12 0,03 0,125 1 
30 Vancomycin = 2 1 4 1 
30 Daptomycin = 2 1 4 1 
30 Tetracycline = 32 8 32 1 
30 Teicoplanin <= 0,5 0,25 1 1 
33 Ampicillin = 1 0,5 2 1 
33 Chloramphenicol = 4 4 16 1 
33 Erythromycin = 4 1 4 1 
33 Gentamicin = 8 4 16 1 
33 Linezolid = 2 1 4 1 
33 Tetracycline = 32 8 32 1 
33 Vancomycin = 2 1 4 1 
34 Chloramphenicol = 8 4 16 1 
34 Ciprofloxacin = 1 0,25 2 1 
34 Daptomycin = 2 1 4 1 
34 Erythromycin = 2 1 4 1 
34 Gentamicin <= 8 4 16 1 
34 Linezolid = 2 1 4 1 
34 Quinopristin-dalfopristin (Synercid) = 8 2 8 1 
34 Tetracycline = 32 8 32 1 
34 Tigecycline = 0,12 0,03 0,125 1 
34 Vancomycin = 4 1 4 1 
34 Ampicillin = 2 0,5 2 1 
34 Teicoplanin <= 0,5 0,25 1 1 
36 Ampicillin = 2 0,5 2 1 
36 Chloramphenicol = 8 4 16 1 
36 Daptomycin = 2 1 4 1 
36 Gentamicin = 16 4 16 1 
36 Linezolid = 2 1 4 1 
36 Quinopristin-dalfopristin (Synercid) = 8 2 8 1 
36 Teicoplanin <= 0,5 0,25 1 1 
36 Tetracycline = 32 8 32 1 
36 Tigecycline = 0,06 0,03 0,125 1 
36 Erythromycin = 2 1 4 1 
36 Ciprofloxacin = 1 0,25 2 1 
36 Vancomycin = 4 1 4 1 
37 Chloramphenicol = 4 4 16 1 
37 Ciprofloxacin = 0,5 0,25 2 1 
37 Erythromycin = 2 1 4 1 
37 Gentamicin <= 8 4 16 1 
37 Linezolid = 2 1 4 1 
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37 Teicoplanin <= 0,5 0,25 1 1 
37 Tetracycline = 16 8 32 1 
37 Vancomycin = 4 1 4 1 
37 Ampicillin = 1 0,5 2 1 
37 Tigecycline = 0,125 0,03 0,125 1 
38 Ampicillin <= 0,5 0,5 2 1 
38 Chloramphenicol = 8 4 16 1 
38 Ciprofloxacin = 1 0,25 2 1 
38 Erythromycin = 2 1 4 1 
38 Gentamicin <= 8 4 16 1 
38 Linezolid = 2 1 4 1 
38 Quinopristin-dalfopristin (Synercid) = 8 2 8 1 
38 Teicoplanin <= 0,5 0,25 1 1 
38 Tigecycline = 0,12 0,03 0,125 1 
38 Daptomycin = 4 1 4 1 
38 Vancomycin = 4 1 4 1 
38 Tetracycline = 32 8 32 1 
39 Ampicillin = 0,5 0,5 2 1 
39 Chloramphenicol = 4 4 16 1 
39 Erythromycin = 2 1 4 1 
39 Gentamicin = 4 4 16 1 
39 Linezolid = 1 1 4 1 
39 Tetracycline = 16 8 32 1 
39 Vancomycin = 2 1 4 1 
40 Chloramphenicol = 8 4 16 1 
40 Ciprofloxacin = 0,25 0,25 2 1 
40 Daptomycin = 1 1 4 1 
40 Erythromycin = 2 1 4 1 
40 Gentamicin = 8 4 16 1 
40 Linezolid = 1 1 4 1 
40 Quinopristin-dalfopristin (Synercid) = 2 2 8 1 
40 Tigecycline = 0,06 0,03 0,125 1 
40 Vancomycin = 2 1 4 1 
40 Tetracycline = 8 8 32 1 
40 Ampicillin = 1 0,5 2 1 
40 Teicoplanin = 0,5 0,25 1 1 
42 Ampicillin = 2 0,5 2 1 
42 Chloramphenicol = 8 4 16 1 
42 Ciprofloxacin = 2 0,25 2 1 
42 Erythromycin = 4 1 4 1 
42 Gentamicin = 16 4 16 1 
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42 Linezolid = 2 1 4 1 
42 Teicoplanin <= 0,5 0,25 1 1 
42 Tigecycline = 0,25 0,03 0,125 0 
42 Vancomycin = 4 1 4 1 
42 Daptomycin = 4 1 4 1 
42 Tetracycline = 32 8 32 1 
42 Quinopristin-dalfopristin (Synercid) = 8 2 8 1 
45 Ampicillin = 1 0,5 2 1 
45 Chloramphenicol = 8 4 16 1 
45 Ciprofloxacin = 1 0,25 2 1 
45 Daptomycin = 1 1 4 1 
45 Erythromycin <= 1 1 4 1 
45 Linezolid = 2 1 4 1 
45 Quinopristin-dalfopristin (Synercid) = 4 2 8 1 
45 Teicoplanin <= 0,5 0,25 1 1 
45 Tigecycline = 0,12 0,03 0,125 1 
45 Vancomycin = 4 1 4 1 
45 Tetracycline = 32 8 32 1 
45 Gentamicin <= 8 4 16 1 
56 Ampicillin = 1 0,5 2 1 
56 Chloramphenicol = 8 4 16 1 
56 Ciprofloxacin = 0,5 0,25 2 1 
56 Daptomycin = 2 1 4 1 
56 Gentamicin <= 8 4 16 1 
56 Linezolid = 2 1 4 1 
56 Teicoplanin <= 0,5 0,25 1 1 
56 Tetracycline = 16 8 32 1 
56 Tigecycline = 0,06 0,03 0,125 1 
56 Vancomycin <= 1 1 4 1 
56 Quinopristin-dalfopristin (Synercid) = 2 2 8 1 
56 Erythromycin <= 1 1 4 1 
58 Ampicillin = 1 0,5 2 1 
58 Ciprofloxacin = 1 0,25 2 1 
58 Daptomycin = 2 1 4 1 
58 Erythromycin <= 1 1 4 1 
58 Gentamicin = 16 4 16 1 
58 Quinopristin-dalfopristin (Synercid) = 8 2 8 1 
58 Teicoplanin <= 0,5 0,25 1 1 
58 Tetracycline = 16 8 32 1 
58 Vancomycin = 4 1 4 1 
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58 Linezolid = 2 1 4 1 
58 Chloramphenicol = 8 4 16 1 
58 Tigecycline = 0,12 0,03 0,125 1 
60 Ampicillin = 1 0,5 2 1 
60 Chloramphenicol = 8 4 16 1 
60 Ciprofloxacin = 0,5 0,25 2 1 
60 Erythromycin = 2 1 4 1 
60 Gentamicin <= 8 4 16 1 
60 Linezolid = 2 1 4 1 
60 Quinopristin-dalfopristin (Synercid) = 8 2 8 1 
60 Tetracycline = 16 8 32 1 
60 Tigecycline = 0,06 0,03 0,125 1 
60 Daptomycin = 2 1 4 1 
60 Vancomycin = 4 1 4 1 
60 Teicoplanin <= 0,5 0,25 1 1 
 




Appendix 6b- Test results from reference strain S. aureus ATCC 29213 
 
LAB ANTIMICROBIAL OPER VALUE MIN_VALUE MAX_VALUE SCORE 
2 Vancomycin <= 1 0,5 2 1 
2 Quinopristin-dalfopristin (Synercid) <= 0,5 0,25 1 1 
2 Linezolid = 2 1 4 1 
2 Mupirocin <= 0,5 
   2 Clindamycin <= 0,12 0,06 0,25 1 
2 Chloramphenicol = 8 2 16 1 
2 Ciprofloxacin <= 0,25 0,12 0,5 1 
2 Erythromycin <= 0,25 0,25 1 1 
2 Cefoxitin = 4 1 4 1 
2 Gentamicin <= 1 0,12 1 1 
2 Sulfamethoxazole <= 64 32 128 1 
2 Tetracycline <= 0,5 0,12 1 1 
2 Tiamulin <= 0,5 
   2 Trimethoprim <= 2 1 4 1 
9 Vancomycin <= 1 0,5 2 1 
9 Quinopristin-dalfopristin (Synercid) <= 0,5 0,25 1 1 
9 Linezolid = 2 1 4 1 
9 Clindamycin <= 0,12 0,06 0,25 1 
9 Chloramphenicol <= 4 2 16 1 
9 Ciprofloxacin <= 0,25 0,12 0,5 1 
9 Erythromycin = 0,5 0,25 1 1 
9 Cefoxitin = 2 1 4 1 
9 Gentamicin <= 1 0,12 1 1 
9 Sulfamethoxazole <= 64 32 128 1 
9 Tetracycline <= 0,5 0,12 1 1 
9 Tiamulin <= 0,5 
   9 Trimethoprim <= 2 1 4 1 
11 Clindamycin <= 0,25 0,06 0,25 1 
11 Chloramphenicol = 4 2 16 1 
11 Ciprofloxacin = 0,25 0,12 0,5 1 
11 Erythromycin = 0,5 0,25 1 1 
11 Cefoxitin = 1 1 4 1 
11 Gentamicin <= 0,5 0,12 1 1 
11 Tetracycline <= 0,5 0,12 1 1 
11 Trimethoprim = 2 1 4 1 
12 Clindamycin <= 0,25 0,06 0,25 1 
12 Chloramphenicol = 4 2 16 1 
12 Ciprofloxacin = 0,25 0,12 0,5 1 
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12 Erythromycin <= 0,25 0,25 1 1 
12 Cefoxitin = 2 1 4 1 
12 Gentamicin <= 0,5 0,12 1 1 
12 Tetracycline <= 0,5 0,12 1 1 
12 Trimethoprim = 1 1 4 1 
17 Vancomycin <= 1 0,5 2 1 
17 Quinopristin-dalfopristin (Synercid) <= 0,5 0,25 1 1 
17 Linezolid = 4 1 4 1 
17 Mupirocin <= 0,5 
   17 Clindamycin <= 0,12 0,06 0,25 1 
17 Chloramphenicol = 16 2 16 1 
17 Ciprofloxacin <= 0,25 0,12 0,5 1 
17 Erythromycin = 0,5 0,25 1 1 
17 Cefoxitin = 4 1 4 1 
17 Gentamicin <= 1 0,12 1 1 
17 Sulfamethoxazole <= 64 32 128 1 
17 Tetracycline = 1 0,12 1 1 
17 Tiamulin = 1 
   17 Trimethoprim <= 2 1 4 1 
19 Vancomycin <= 1 0,5 2 1 
19 Quinopristin-dalfopristin (Synercid) <= 0,5 0,25 1 1 
19 Linezolid = 2 1 4 1 
19 Mupirocin <= 0,5 
   19 Clindamycin <= 0,12 0,06 0,25 1 
19 Chloramphenicol = 8 2 16 1 
19 Ciprofloxacin <= 0,25 0,12 0,5 1 
19 Erythromycin = 0,5 0,25 1 1 
19 Cefoxitin = 2 1 4 1 
19 Gentamicin <= 1 0,12 1 1 
19 Sulfamethoxazole <= 64 32 128 1 
19 Tetracycline <= 0,5 0,12 1 1 
19 Tiamulin = 0,5 
   19 Trimethoprim <= 2 1 4 1 
20 Vancomycin <= 1 0,5 2 1 
20 Quinopristin-dalfopristin (Synercid) = 1 0,25 1 1 
20 Linezolid = 4 1 4 1 
20 Mupirocin <= 0,5 
   20 Clindamycin <= 0,12 0,06 0,25 1 
20 Chloramphenicol = 16 2 16 1 
20 Ciprofloxacin <= 0,25 0,12 0,5 1 
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20 Erythromycin = 0,5 0,25 1 1 
20 Cefoxitin = 4 1 4 1 
20 Gentamicin <= 1 0,12 1 1 
20 Sulfamethoxazole = 128 32 128 1 
20 Tetracycline = 1 0,12 1 1 
20 Tiamulin = 1 
   20 Trimethoprim <= 2 1 4 1 
21 Quinopristin-dalfopristin (Synercid) = 1 0,25 1 1 
21 Tetracycline = 1 0,12 1 1 
21 Vancomycin <= 1 0,5 2 1 
21 Linezolid = 2 1 4 1 
21 Clindamycin <= 0,12 0,06 0,25 1 
21 Chloramphenicol = 8 2 16 1 
21 Ciprofloxacin <= 0,25 0,12 0,5 1 
21 Erythromycin = 0,5 0,25 1 1 
21 Cefoxitin = 4 1 4 1 
21 Gentamicin <= 1 0,12 1 1 
21 Sulfamethoxazole <= 64 32 128 1 
21 Trimethoprim <= 2 1 4 1 
22 Gentamicin <= 1 0,12 1 1 
22 Vancomycin <= 1 0,5 2 1 
22 Quinopristin-dalfopristin (Synercid) <= 0,5 0,25 1 1 
22 Linezolid = 2 1 4 1 
22 Clindamycin <= 0,12 0,06 0,25 1 
22 Chloramphenicol = 8 2 16 1 
22 Ciprofloxacin = 0,5 0,12 0,5 1 
22 Erythromycin = 0,5 0,25 1 1 
22 Cefoxitin = 2 1 4 1 
22 Sulfamethoxazole <= 64 32 128 1 
22 Tetracycline <= 0,5 0,12 1 1 
22 Trimethoprim <= 2 1 4 1 
23 Ciprofloxacin <= 0,25 0,12 0,5 1 
23 Vancomycin <= 1 0,5 2 1 
23 Quinopristin-dalfopristin (Synercid) <= 0,5 0,25 1 1 
23 Linezolid = 2 1 4 1 
23 Clindamycin <= 0,12 0,06 0,25 1 
23 Chloramphenicol = 8 2 16 1 
23 Erythromycin = 0,5 0,25 1 1 
23 Cefoxitin = 1 1 4 1 
23 Gentamicin <= 1 0,12 1 1 
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23 Sulfamethoxazole <= 64 32 128 1 
23 Tetracycline <= 0,5 0,12 1 1 
23 Trimethoprim <= 2 1 4 1 
25 Clindamycin = 0,12 0,06 0,25 1 
25 Erythromycin = 0,25 0,25 1 1 
25 Sulfamethoxazole-Trimethoprim <= 0,12 0 0,5 1 
25 Tetracycline = 0,5 0,12 1 1 
26 Vancomycin <= 1 0,5 2 1 
26 Quinopristin-dalfopristin (Synercid) <= 0,5 0,25 1 1 
26 Linezolid = 2 1 4 1 
26 Mupirocin <= 0,5 
   26 Clindamycin = 0,25 0,06 0,25 1 
26 Chloramphenicol = 8 2 16 1 
26 Ciprofloxacin = 0,5 0,12 0,5 1 
26 Erythromycin <= 0,25 0,25 1 1 
26 Cefoxitin = 4 1 4 1 
26 Gentamicin <= 1 0,12 1 1 
26 Sulfamethoxazole <= 64 32 128 1 
26 Sulfamethoxazole-Trimethoprim = 0,25 0 0,5 1 
26 Tetracycline <= 0,5 0,12 1 1 
26 Tiamulin <= 0,5 
   26 Trimethoprim <= 2 1 4 1 
29 Vancomycin <= 1 0,5 2 1 
29 Quinopristin-dalfopristin (Synercid) <= 0,5 0,25 1 1 
29 Linezolid = 2 1 4 1 
29 Clindamycin <= 0,12 0,06 0,25 1 
29 Chloramphenicol = 8 2 16 1 
29 Ciprofloxacin <= 0,25 0,12 0,5 1 
29 Erythromycin = 0,25 0,25 1 1 
29 Cefoxitin = 4 1 4 1 
29 Gentamicin <= 1 0,12 1 1 
29 Sulfamethoxazole <= 64 32 128 1 
29 Tetracycline <= 0,5 0,12 1 1 
29 Trimethoprim <= 2 1 4 1 
30 Vancomycin <= 1 0,5 2 1 
30 Trimethoprim <= 2 1 4 1 
30 Linezolid = 2 1 4 1 
30 Mupirocin <= 0,5 
   30 Clindamycin <= 0,12 0,06 0,25 1 
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30 Chloramphenicol = 8 2 16 1 
30 Ciprofloxacin <= 0,25 0,12 0,5 1 
30 Erythromycin <= 0,5 0,25 1 1 
30 Cefoxitin = 4 1 4 1 
30 Gentamicin <= 1 0,12 1 1 
30 Sulfamethoxazole <= 64 32 128 1 
30 Tetracycline <= 0,5 0,12 1 1 
30 Tiamulin <= 0,5 
   30 Quinopristin-dalfopristin (Synercid) <= 0,5 0,25 1 1 
31 Erythromycin <= 0,5 0,25 1 1 
31 Trimethoprim <= 2 1 4 1 
31 Quinopristin-dalfopristin (Synercid) <= 1 0,25 1 1 
31 Linezolid <= 1 1 4 1 
31 Mupirocin <= 1 
   31 Clindamycin <= 0,25 0,06 0,25 1 
31 Chloramphenicol <= 16 2 16 1 
31 Ciprofloxacin <= 0,25 0,12 0,5 1 
31 Cefoxitin <= 4 1 4 1 
31 Gentamicin <= 2 0,12 1 1 
31 Sulfamethoxazole <= 128 32 128 1 
31 Sulfamethoxazole-Trimethoprim <= 0,5 0 0,5 1 
31 Tetracycline <= 1 0,12 1 1 
31 Tiamulin <= 2 
   31 Vancomycin <= 1 0,5 2 1 
33 Gentamicin <= 0,5 0,12 1 1 
33 Trimethoprim = 1 1 4 1 
33 Clindamycin <= 0,25 0,06 0,25 1 
33 Chloramphenicol = 8 2 16 1 
33 Ciprofloxacin = 0,25 0,12 0,5 1 
33 Erythromycin = 1 0,25 1 1 
33 Cefoxitin = 4 1 4 1 
33 Tetracycline <= 0,5 0,12 1 1 
34 Sulfamethoxazole = 128 32 128 1 
34 Gentamicin <= 1 0,12 1 1 
34 Tetracycline = 1 0,12 1 1 
34 Trimethoprim <= 2 1 4 1 
34 Mupirocin <= 0,5 
   34 Tiamulin = 1 
   34 Vancomycin <= 1 0,5 2 1 
34 Quinopristin-dalfopristin (Synercid) <= 0,5 0,25 1 1 
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34 Linezolid = 4 1 4 1 
34 Clindamycin <= 0,12 0,06 0,25 1 
34 Chloramphenicol = 16 2 16 1 
34 Ciprofloxacin <= 0,25 0,12 0,5 1 
34 Erythromycin = 0,5 0,25 1 1 
34 Cefoxitin = 4 1 4 1 
36 Tetracycline <= 0,5 0,12 1 1 
36 Tiamulin <= 0,5 
   36 Trimethoprim <= 2 1 4 1 
36 Vancomycin <= 1 0,5 2 1 
36 Quinopristin-dalfopristin (Synercid) <= 0,5 0,25 1 1 
36 Linezolid = 2 1 4 1 
36 Mupirocin <= 0,5 
   36 Clindamycin <= 0,12 0,06 0,25 1 
36 Chloramphenicol = 8 2 16 1 
36 Ciprofloxacin <= 0,25 0,12 0,5 1 
36 Erythromycin <= 0,25 0,25 1 1 
36 Cefoxitin = 4 1 4 1 
36 Gentamicin <= 1 0,12 1 1 
36 Sulfamethoxazole <= 64 32 128 1 
37 Vancomycin <= 1 0,5 2 1 
37 Chloramphenicol = 8 2 16 1 
37 Ciprofloxacin = 0,25 0,12 0,5 1 
37 Erythromycin = 0,25 0,25 1 1 
37 Cefoxitin = 4 1 4 1 
37 Gentamicin = 0,25 0,12 1 1 
37 Sulfamethoxazole = 16 32 128 0 
37 Tetracycline = 0,5 0,12 1 1 
37 Trimethoprim = 1 1 4 1 
37 Linezolid = 2 1 4 1 
39 Clindamycin <= 0,25 0,06 0,25 1 
39 Chloramphenicol = 8 2 16 1 
39 Ciprofloxacin = 0,5 0,12 0,5 1 
39 Erythromycin = 1 0,25 1 1 
39 Gentamicin <= 0,5 0,12 1 1 
39 Tetracycline <= 0,5 0,12 1 1 
39 Trimethoprim = 2 1 4 1 
40 Vancomycin = 1 0,5 2 1 
40 Gentamicin = 1 0,12 1 1 
40 Clindamycin = 0,12 0,06 0,25 1 
40 Chloramphenicol = 4 2 16 1 
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40 Ciprofloxacin = 0,25 0,12 0,5 1 
40 Erythromycin = 0,25 0,25 1 1 
40 Cefoxitin = 2 1 4 1 
40 Sulfamethoxazole = 64 32 128 1 
40 Sulfamethoxazole-Trimethoprim <= 0,5 0 0,5 1 
40 Tetracycline = 0,5 0,12 1 1 
40 Tiamulin = 0,5 
   40 Trimethoprim = 2 1 4 1 
40 Quinopristin-dalfopristin (Synercid) = 0,5 0,25 1 1 
40 Linezolid = 1 1 4 1 
42 Ciprofloxacin = 0,5 0,12 0,5 1 
42 Tetracycline <= 0,5 0,12 1 1 
42 Cefoxitin = 4 1 4 1 
42 Gentamicin <= 1 0,12 1 1 
42 Sulfamethoxazole <= 64 32 128 1 
42 Tiamulin = 1 
   42 Trimethoprim <= 2 1 4 1 
42 Vancomycin <= 1 0,5 2 1 
42 Quinopristin-dalfopristin (Synercid) <= 0,5 0,25 1 1 
42 Linezolid = 4 1 4 1 
42 Clindamycin <= 0,12 0,06 0,25 1 
42 Chloramphenicol = 8 2 16 1 
42 Mupirocin <= 0,5 
   42 Erythromycin = 0,5 0,25 1 1 
45 Vancomycin <= 1 0,5 2 1 
45 Trimethoprim <= 2 1 4 1 
45 Linezolid = 2 1 4 1 
45 Mupirocin <= 0,5 
   45 Clindamycin <= 0,12 0,06 0,25 1 
45 Chloramphenicol = 8 2 16 1 
45 Ciprofloxacin = 0,5 0,12 0,5 1 
45 Erythromycin <= 0,25 0,25 1 1 
45 Cefoxitin = 4 1 4 1 
45 Gentamicin <= 1 0,12 1 1 
45 Sulfamethoxazole = 128 32 128 1 
45 Tetracycline = 1 0,12 1 1 
45 Tiamulin <= 0,5 
   45 Quinopristin-dalfopristin (Synercid) <= 0,5 0,25 1 1 
56 Vancomycin <= 1 0,5 2 1 
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56 Ciprofloxacin <= 0,25 0,12 0,5 1 
56 Linezolid = 2 1 4 1 
56 Mupirocin <= 0,5 
   56 Clindamycin <= 0,12 0,06 0,25 1 
56 Chloramphenicol = 8 2 16 1 
56 Erythromycin <= 0,25 0,25 1 1 
56 Cefoxitin = 1 1 4 1 
56 Gentamicin <= 1 0,12 1 1 
56 Sulfamethoxazole <= 64 32 128 1 
56 Tetracycline <= 0,5 0,12 1 1 
56 Tiamulin = 1 
   56 Trimethoprim <= 2 1 4 1 
56 Quinopristin-dalfopristin (Synercid) <= 0,5 0,25 1 1 
58 Vancomycin <= 1 0,5 2 1 
58 Trimethoprim <= 2 1 4 1 
58 Linezolid = 2 1 4 1 
58 Mupirocin <= 0,5 
   58 Clindamycin <= 0,12 0,06 0,25 1 
58 Chloramphenicol = 8 2 16 1 
58 Ciprofloxacin <= 0,25 0,12 0,5 1 
58 Erythromycin <= 0,25 0,25 1 1 
58 Cefoxitin = 4 1 4 1 
58 Gentamicin <= 1 0,12 1 1 
58 Sulfamethoxazole <= 64 32 128 1 
58 Tetracycline <= 0,5 0,12 1 1 
58 Tiamulin <= 0,5 





Appendix 6c- Test results from reference strain E. coli ATCC 25922 
 
LAB  ANTIMICROBIAL  PANEL  OPERATOR VALUE  MIN_VALUE MAX_VALUE  SCORE
2  Ampicillin  1  =  8 2 8  1
2  Azithromycin  1  =  4
2  Cefotaxime  1  <=  0,25 0,03 0,12  1
2  Ceftazidime  1  <=  0,5 0,06 0,5  1
2  Chloramphenicol  1  <=  8 2 8  1
2  Ciprofloxacin  1  <=  0,015 0,004 0,015  1
2  Colistin  1  <=  1 0,25 2  1
2  Gentamicin  1  <=  0,5 0,25 1  1
2  Meropenem  1  <=  0,03 0,008 0,06  1
2  Nalidixic acid  1  <=  4 1 4  1
2  Sulfamethoxazole  1  =  16 8 32  1
2  Tetracycline  1  <=  2 0,5 2  1
2  Tigecycline  1  <=  0,25 0,03 0,25  1
2  Trimethoprim  1  =  0,5 0,5 2  1
2  Cefepime  2  <=  0,06 0,015 0,12  1
2  Cefotaxime  2  <=  0,25 0,03 0,12  1
2 
Cefotaxime/clavulanic 
acid  2  <=  0,06
2  Cefoxitin  2  =  2 2 8  1
2  Ceftazidime  2  <=  0,25 0,06 0,5  1
2 
Ceftazidime/clavulanic 
acid  2  <=  0,12
2  Ertapenem  2  <=  0,015 0,004 0,015  1
2  Imipenem  2  <=  0,12 0,06 0,25  1
2  Meropenem  2  <=  0,03 0,008 0,06  1
2  Temocillin  2  =  8
9  Ampicillin  1  =  4 2 8  1
9  Ceftazidime  1  <=  0,5 0,06 0,5  1
9  Chloramphenicol  1  <=  8 2 8  1
9  Ciprofloxacin  1  <=  0,015 0,004 0,015  1
9  Colistin  1  <=  1 0,25 2  1
9  Gentamicin  1  <=  0,5 0,25 1  1
9  Meropenem  1  <=  0,03 0,008 0,06  1
9  Nalidixic acid  1  <=  4 1 4  1
9  Sulfamethoxazole  1  =  16 8 32  1
9  Tetracycline  1  <=  2 0,5 2  1
9  Tigecycline  1  <=  0,25 0,03 0,25  1
9  Trimethoprim  1  =  1 0,5 2  1
9  Cefepime  2  =  0,06 0,015 0,12  1
9  Cefotaxime  2  <=  0,25 0,03 0,12  1
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9  Ceftazidime  2  <=  0,25 0,06 0,5  1
9  Ertapenem  2  <=  0,015 0,004 0,015  1
9  Imipenem  2  <=  0,12 0,06 0,25  1
9  Meropenem  2  <=  0,03 0,008 0,06  1
11  Ampicillin  1  =  2 2 8  1
11  Azithromycin  1  =  8
11  Cefotaxime  1  <=  0,25 0,03 0,12  1
11  Ceftazidime  1  <=  0,5 0,06 0,5  1
11  Chloramphenicol  1  <=  8 2 8  1
11  Ciprofloxacin  1  <=  0,015 0,004 0,015  1
11  Colistin  1  <=  1 0,25 2  1
11  Gentamicin  1  <=  0,5 0,25 1  1
11  Meropenem  1  <=  0,03 0,008 0,06  1
11  Nalidixic acid  1  <=  4 1 4  1
11  Sulfamethoxazole  1  =  16 8 32  1
11  Tetracycline  1  <=  2 0,5 2  1
11  Tigecycline  1  <=  0,25 0,03 0,25  1
11  Trimethoprim  1  =  0,5 0,5 2  1
11  Cefepime  2  <=  0,6 0,015 0,12  1
11  Cefotaxime  2  <=  0,25 0,03 0,12  1
11 
Cefotaxime/clavulanic 
acid  2  <=  0,06
11  Cefoxitin  2  =  2 2 8  1
11  Ceftazidime  2  <=  0,25 0,06 0,5  1
11 
Ceftazidime/clavulanic 
acid  2  <=  0,12
11  Ertapenem  2  <=  0,015 0,004 0,015  1
11  Imipenem  2  <=  0,12 0,06 0,25  1
11  Meropenem  2  <=  0,03 0,008 0,06  1
11  Temocillin  2  =  8
12  Ampicillin  1  =  8 2 8  1
12  Azithromycin  1  =  8
12  Cefotaxime  1  <=  0,25 0,03 0,12  1
12  Ceftazidime  1  <=  0,5 0,06 0,5  1
12  Chloramphenicol  1  <=  8 2 8  1
12  Ciprofloxacin  1  <=  0,015 0,004 0,015  1
12  Colistin  1  <=  1 0,25 2  1
12  Gentamicin  1  <=  0,5 0,25 1  1
12  Meropenem  1  <=  0,03 0,008 0,06  1
12  Nalidixic acid  1  <=  4 1 4  1
12  Sulfamethoxazole  1  <=  8 8 32  1
12  Tetracycline  1  <=  2 0,5 2  1




LAB  ANTIMICROBIAL  PANEL  OPERATOR VALUE  MIN_VALUE MAX_VALUE  SCORE
12  Trimethoprim  1  =  1 0,5 2  1
12  Cefepime  2  <=  0,06 0,015 0,12  1
12  Cefotaxime  2  <=  0,25 0,03 0,12  1
12  Cefoxitin  2  =  2 2 8  1
12  Ceftazidime  2  <=  0,25 0,06 0,5  1
12  Ertapenem  2  <=  0,015 0,004 0,015  1
12  Imipenem  2  =  0,25 0,06 0,25  1
12  Meropenem  2  <=  0,03 0,008 0,06  1
12  Temocillin  2  =  16
16  Ampicillin  1  =  4 2 8  1
16  Azithromycin  1  =  4
16  Cefotaxime  1  <=  0,25 0,03 0,12  1
16  Ceftazidime  1  <=  0,5 0,06 0,5  1
16  Chloramphenicol  1  <=  8 2 8  1
16  Ciprofloxacin  1  <=  0,015 0,004 0,015  1
16  Colistin  1  <=  1 0,25 2  1
16  Gentamicin  1  <=  0,5 0,25 1  1
16  Meropenem  1  <=  0,03 0,008 0,06  1
16  Nalidixic acid  1  <=  4 1 4  1
16  Sulfamethoxazole  1  =  64 8 32  0
16  Tetracycline  1  <=  2 0,5 2  1
16  Tigecycline  1  <=  0,25 0,03 0,25  1
16  Trimethoprim  1  =  1 0,5 2  1
16  Cefepime  2  <=  0,06 0,015 0,12  1
16  Cefotaxime  2  <=  0,25 0,03 0,12  1
16 
Cefotaxime/clavulanic 
acid  2  <=  0,06
16  Cefoxitin  2  =  4 2 8  1
16  Ceftazidime  2  <=  0,25 0,06 0,5  1
16 
Ceftazidime/clavulanic 
acid  2  =  0,25
16  Ertapenem  2  <=  0,015 0,004 0,015  1
16  Imipenem  2  =  0,25 0,06 0,25  1
16  Meropenem  2  <=  0,03 0,008 0,06  1
16  Temocillin  2  =  16
17  Ampicillin  1  =  4 2 8  1
17  Azithromycin  1  =  8
17  Cefotaxime  1  <=  0,12 0,03 0,12  1
17  Ceftazidime  1  <=  0,5 0,06 0,5  1
17  Chloramphenicol  1  <=  8 2 8  1
17  Ciprofloxacin  1  <=  0,015 0,004 0,015  1
17  Colistin  1  <=  1 0,25 2  1
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17  Meropenem  1  <=  0,03 0,008 0,06  1
17  Nalidixic acid  1  <=  4 1 4  1
17  Sulfamethoxazole  1  =  32 8 32  1
17  Tetracycline  1  <=  2 0,5 2  1
17  Tigecycline  1  <=  0,25 0,03 0,25  1
17  Trimethoprim  1  =  0,5 0,5 2  1
17  Cefepime  2  <=  0,06 0,015 0,12  1
17  Cefotaxime  2  <=  0,12 0,03 0,12  1
17 
Cefotaxime/clavulanic 
acid  2  <=  0,06
17  Cefoxitin  2  =  4 2 8  1
17  Ceftazidime  2  <=  0,25 0,06 0,5  1
17 
Ceftazidime/clavulanic 
acid  2  <=  0,12
17  Ertapenem  2  <=  0,015 0,004 0,015  1
17  Imipenem  2  <=  0,12 0,06 0,25  1
17  Meropenem  2  <=  0,03 0,008 0,06  1
17  Temocillin  2  =  8
19  Ampicillin  1  =  4 2 8  1
19  Azithromycin  1  =  4
19  Cefotaxime  1  <=  0,25 0,03 0,12  1
19  Ceftazidime  1  <=  0,5 0,06 0,5  1
19  Chloramphenicol  1  <=  8 2 8  1
19  Ciprofloxacin  1  <=  0,015 0,004 0,015  1
19  Colistin  1  <=  1 0,25 2  1
19  Gentamicin  1  <=  0,5 0,25 1  1
19  Meropenem  1  <=  0,03 0,008 0,06  1
19  Nalidixic acid  1  =  8 1 4  0
19  Sulfamethoxazole  1  =  32 8 32  1
19  Tetracycline  1  <=  2 0,5 2  1
19  Tigecycline  1  <=  0,25 0,03 0,25  1
19  Trimethoprim  1  =  0,5 0,5 2  1
19  Cefepime  2  <=  0,06 0,015 0,12  1
19  Cefotaxime  2  <=  0,25 0,03 0,12  1
19 
Cefotaxime/clavulanic 
acid  2  <=  0,06
19  Cefoxitin  2  =  4 2 8  1
19  Ceftazidime  2  <=  0,25 0,06 0,5  1
19 
Ceftazidime/clavulanic 
acid  2  <=  0,12
19  Ertapenem  2  <=  0,015 0,004 0,015  1
19  Imipenem  2  <=  0,12 0,06 0,25  1
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19  Temocillin  2  =  8
20  Ampicillin  1  =  4 2 8  1
20  Azithromycin  1  =  4
20  Cefotaxime  1  <=  0,25 0,03 0,12  1
20  Ceftazidime  1  <=  0,5 0,06 0,5  1
20  Chloramphenicol  1  <=  8 2 8  1
20  Ciprofloxacin  1  <=  0,015 0,004 0,015  1
20  Colistin  1  <=  1 0,25 2  1
20  Gentamicin  1  <=  0,5 0,25 1  1
20  Meropenem  1  <=  0,03 0,008 0,06  1
20  Nalidixic acid  1  <=  4 1 4  1
20  Sulfamethoxazole  1  =  32 8 32  1
20  Tetracycline  1  <=  2 0,5 2  1
20  Tigecycline  1  <=  0,25 0,03 0,25  1
20  Trimethoprim  1  =  0,5 0,5 2  1
20  Cefepime  2  <=  0,06 0,015 0,12  1
20  Cefotaxime  2  <=  0,25 0,03 0,12  1
20 
Cefotaxime/clavulanic 
acid  2  <=  0,06
20  Cefoxitin  2  =  4 2 8  1
20  Ceftazidime  2  <=  0,25 0,06 0,5  1
20 
Ceftazidime/clavulanic 
acid  2  <=  0,12
20  Ertapenem  2  <=  0,015 0,004 0,015  1
20  Imipenem  2  =  0,25 0,06 0,25  1
20  Meropenem  2  <=  0,03 0,008 0,06  1
20  Temocillin  2  =  16
21  Ampicillin  1  =  4 2 8  1
21  Cefotaxime  1  <=  0,25 0,03 0,12  1
21  Ceftazidime  1  =  0,5 0,06 0,5  1
21  Chloramphenicol  1  =  8 2 8  1
21  Ciprofloxacin  1  <=  0,015 0,004 0,015  1
21  Colistin  1  =  1 0,25 2  1
21  Gentamicin  1  =  0,5 0,25 1  1
21  Meropenem  1  =  0,03 0,008 0,06  1
21  Nalidixic acid  1  =  4 1 4  1
21  Sulfamethoxazole  1  =  32 8 32  1
21  Tetracycline  1  =  2 0,5 2  1
21  Tigecycline  1  =  0,25 0,03 0,25  1
21  Trimethoprim  1  =  1 0,5 2  1
21  Cefepime  2  =  0,06 0,015 0,12  1
21  Cefoxitin  2  =  2 2 8  1




LAB  ANTIMICROBIAL  PANEL  OPERATOR VALUE  MIN_VALUE MAX_VALUE  SCORE
21  Imipenem  2  <=  0,12 0,06 0,25  1
21  Meropenem  2  <=  0,03 0,008 0,06  1
22  Ampicillin  1  =  4 2 8  1
22  Azithromycin  1  =  4
22  Cefotaxime  1  <=  0,25 0,03 0,12  1
22  Ceftazidime  1  <=  0,5 0,06 0,5  1
22  Chloramphenicol  1  <=  8 2 8  1
22  Ciprofloxacin  1  <=  0,015 0,004 0,015  1
22  Colistin  1  <=  1 0,25 2  1
22  Gentamicin  1  =  1 0,25 1  1
22  Meropenem  1  <=  0,03 0,008 0,06  1
22  Nalidixic acid  1  <=  4 1 4  1
22  Sulfamethoxazole  1  =  16 8 32  1
22  Tetracycline  1  <=  2 0,5 2  1
22  Tigecycline  1  <=  0,25 0,03 0,25  1
22  Trimethoprim  1  =  2 0,5 2  1
23  Ampicillin  1  =  2 2 8  1
23  Azithromycin  1  <=  2
23  Cefotaxime  1  <=  0,25 0,03 0,12  1
23  Ceftazidime  1  <=  0,5 0,06 0,5  1
23  Chloramphenicol  1  <=  8 2 8  1
23  Ciprofloxacin  1  <=  0,015 0,004 0,015  1
23  Colistin  1  <=  1 0,25 2  1
23  Gentamicin  1  <=  0,5 0,25 1  1
23  Meropenem  1  <=  0,03 0,008 0,06  1
23  Nalidixic acid  1  <=  4 1 4  1
23  Sulfamethoxazole  1  =  16 8 32  1
23  Tetracycline  1  <=  2 0,5 2  1
23  Tigecycline  1  <=  0,25 0,03 0,25  1
23  Trimethoprim  1  =  0,5 0,5 2  1
23  Cefepime  2  <=  0,06 0,015 0,12  1
23  Cefotaxime  2  <=  0,25 0,03 0,12  1
23  Cefoxitin  2  =  2 2 8  1
23  Ceftazidime  2  <=  0,25 0,06 0,5  1
23  Ertapenem  2  <=  0,015 0,004 0,015  1
23  Imipenem  2  <=  0,12 0,06 0,25  1
23  Meropenem  2  <=  0,03 0,008 0,06  1
25  Ampicillin  1  =  8 2 8  1
25  Azithromycin  1  =  4
25  Cefotaxime  1  <=  0,25 0,03 0,12  1
25  Ceftazidime  1  <=  0,5 0,06 0,5  1
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25  Ciprofloxacin  1  <=  0,015 0,004 0,015  1
25  Colistin  1  =  2 0,25 2  1
25  Gentamicin  1  <=  0,5 0,25 1  1
25  Meropenem  1  <=  0,03 0,008 0,06  1
25  Nalidixic acid  1  <=  4 1 4  1
25  Sulfamethoxazole  1  <=  8 8 32  1
25  Tetracycline  1  <=  2 0,5 2  1
25  Tigecycline  1  <=  0,25 0,03 0,25  1
25  Trimethoprim  1  =  0,5 0,5 2  1
25  Cefepime  2  <=  0,06 0,015 0,12  1
25  Cefotaxime  2  <=  0,25 0,03 0,12  1
25 
Cefotaxime/clavulanic 
acid  2  <=  0,06
25  Cefoxitin  2  =  4 2 8  1
25  Ceftazidime  2  <=  0,25 0,06 0,5  1
25 
Ceftazidime/clavulanic 
acid  2  =  0,25
25  Ertapenem  2  <=  0,015 0,004 0,015  1
25  Imipenem  2  =  0,25 0,06 0,25  1
25  Meropenem  2  <=  0,03 0,008 0,06  1
25  Temocillin  2  =  32
26  Ampicillin  1  =  2 2 8  1
26  Azithromycin  1  <=  2
26  Cefotaxime  1  <=  0,25 0,03 0,12  1
26  Ceftazidime  1  <=  0,5 0,06 0,5  1
26  Chloramphenicol  1  <=  8 2 8  1
26  Ciprofloxacin  1  <=  0,015 0,004 0,015  1
26  Colistin  1  <=  1 0,25 2  1
26  Gentamicin  1  <=  0,5 0,25 1  1
26  Meropenem  1  <=  0,03 0,008 0,06  1
26  Nalidixic acid  1  <=  4 1 4  1
26  Sulfamethoxazole  1  <=  8 8 32  1
26  Tetracycline  1  <=  2 0,5 2  1
26  Tigecycline  1  <=  0,25 0,03 0,25  1
26  Trimethoprim  1  =  0,5 0,5 2  1
29  Ampicillin  1  =  2 2 8  1
29  Cefotaxime  1  <=  0,25 0,03 0,12  1
29  Ceftazidime  1  <=  0,5 0,06 0,5  1
29  Chloramphenicol  1  <=  8 2 8  1
29  Ciprofloxacin  1  <=  0,015 0,004 0,015  1
29  Colistin  1  <=  1 0,25 2  1
29  Gentamicin  1  =  1 0,25 1  1
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29  Nalidixic acid  1  <=  4 1 4  1
29  Sulfamethoxazole  1  =  32 8 32  1
29  Tetracycline  1  <=  2 0,5 2  1
29  Tigecycline  1  <=  0,25 0,03 0,25  1
29  Trimethoprim  1  =  0,5 0,5 2  1
29  Cefepime  2  <=  0,06 0,015 0,12  1
29  Cefotaxime  2  <=  0,25 0,03 0,12  1
29  Cefoxitin  2  =  2 2 8  1
29  Ceftazidime  2  <=  0,25 0,06 0,5  1
29  Ertapenem  2  <=  0,015 0,004 0,015  1
29  Imipenem  2  <=  0,12 0,06 0,25  1
29  Meropenem  2  <=  0,03 0,008 0,06  1
30  Ampicillin  1  =  4 2 8  1
30  Azithromycin  1  =  4
30  Cefotaxime  1  <=  0,25 0,03 0,12  1
30  Ceftazidime  1  <=  0,5 0,06 0,5  1
30  Chloramphenicol  1  <=  8 2 8  1
30  Ciprofloxacin  1  <=  0,015 0,004 0,015  1
30  Colistin  1  <=  1 0,25 2  1
30  Gentamicin  1  <=  0,5 0,25 1  1
30  Meropenem  1  <=  0,03 0,008 0,06  1
30  Nalidixic acid  1  <=  4 1 4  1
30  Sulfamethoxazole  1  =  16 8 32  1
30  Tetracycline  1  <=  2 0,5 2  1
30  Tigecycline  1  <=  0,25 0,03 0,25  1
30  Trimethoprim  1  =  0,5 0,5 2  1
30  Cefepime  2  <=  0,06 0,015 0,12  1
30  Cefotaxime  2  <=  0,25 0,03 0,12  1
30 
Cefotaxime/clavulanic 
acid  2  <=  0,06
30  Cefoxitin  2  =  2 2 8  1
30  Ceftazidime  2  <=  0,25 0,06 0,5  1
30 
Ceftazidime/clavulanic 
acid  2  =  0,25
30  Ertapenem  2  <=  0,015 0,004 0,015  1
30  Imipenem  2  =  0,25 0,06 0,25  1
30  Meropenem  2  <=  0,03 0,008 0,06  1
30  Temocillin  2  =  16
33  Ampicillin  1  =  4 2 8  1
33  Azithromycin  1  =  4
33  Cefotaxime  1  <=  0,25 0,03 0,12  1
33  Ceftazidime  1  <=  0,5 0,06 0,5  1
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33  Ciprofloxacin  1  <=  0,015 0,004 0,015  1
33  Colistin  1  <=  1 0,25 2  1
33  Gentamicin  1  <=  0,5 0,25 1  1
33  Meropenem  1  <=  0,03 0,008 0,06  1
33  Nalidixic acid  1  <=  4 1 4  1
33  Sulfamethoxazole  1  =  32 8 32  1
33  Tetracycline  1  <=  2 0,5 2  1
33  Tigecycline  1  <=  0,25 0,03 0,25  1
33  Trimethoprim  1  =  0,5 0,5 2  1
33  Cefepime  2  <=  0,06 0,015 0,12  1
33  Cefotaxime  2  <=  0,25 0,03 0,12  1
33 
Cefotaxime/clavulanic 
acid  2  <=  0,06
33  Cefoxitin  2  =  4 2 8  1
33  Ceftazidime  2  <=  0,25 0,06 0,5  1
33 
Ceftazidime/clavulanic 
acid  2  <=  0,12
33  Ertapenem  2  <=  0,015 0,004 0,015  1
33  Imipenem  2  =  0,25 0,06 0,25  1
33  Meropenem  2  <=  0,03 0,008 0,06  1
33  Temocillin  2  =  8
34  Ampicillin  1  =  4 2 8  1
34  Azithromycin  1  =  4
34  Cefotaxime  1  <=  0,25 0,03 0,12  1
34  Ceftazidime  1  <=  0,5 0,06 0,5  1
34  Chloramphenicol  1  <=  8 2 8  1
34  Ciprofloxacin  1  <=  0,015 0,004 0,015  1
34  Colistin  1  <=  1 0,25 2  1
34  Gentamicin  1  <=  0,5 0,25 1  1
34  Meropenem  1  =  0,06 0,008 0,06  1
34  Nalidixic acid  1  <=  4 1 4  1
34  Sulfamethoxazole  1  =  16 8 32  1
34  Tetracycline  1  <=  2 0,5 2  1
34  Tigecycline  1  <=  0,25 0,03 0,25  1
34  Trimethoprim  1  =  1 0,5 2  1
34  Cefepime  2  <=  0,06 0,015 0,12  1
34  Cefotaxime  2  <=  0,25 0,03 0,12  1
34 
Cefotaxime/clavulanic 
acid  2  <=  0,06
34  Cefoxitin  2  =  4 2 8  1
34  Ceftazidime  2  <=  0,25 0,06 0,5  1
34 
Ceftazidime/clavulanic 
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34  Ertapenem  2  <=  0,015 0,004 0,015  1
34  Imipenem  2  <=  0,12 0,06 0,25  1
34  Meropenem  2  <=  0,03 0,008 0,06  1
34  Temocillin  2  =  8
36  Ampicillin  1  =  8 2 8  1
36  Azithromycin  1  =  4
36  Cefotaxime  1  <=  0,25 0,03 0,12  1
36  Ceftazidime  1  <=  0,5 0,06 0,5  1
36  Chloramphenicol  1  <=  8 2 8  1
36  Ciprofloxacin  1  <=  0,015 0,004 0,015  1
36  Colistin  1  <=  1 0,25 2  1
36  Gentamicin  1  <=  0,5 0,25 1  1
36  Meropenem  1  <=  0,03 0,008 0,06  1
36  Nalidixic acid  1  <=  4 1 4  1
36  Sulfamethoxazole  1  =  16 8 32  1
36  Tetracycline  1  <=  2 0,5 2  1
36  Tigecycline  1  <=  0,25 0,03 0,25  1
36  Trimethoprim  1  =  0,5 0,5 2  1
36  Cefepime  2  <=  0,06 0,015 0,12  1
36  Cefotaxime  2  <=  0,25 0,03 0,12  1
36 
Cefotaxime/clavulanic 
acid  2  <=  0,06
36  Cefoxitin  2  =  4 2 8  1
36  Ceftazidime  2  <=  0,25 0,06 0,5  1
36 
Ceftazidime/clavulanic 
acid  2  <=  0,25
36  Ertapenem  2  <=  0,015 0,004 0,015  1
36  Imipenem  2  =  0,25 0,06 0,25  1
36  Meropenem  2  <=  0,03 0,008 0,06  1
36  Temocillin  2  =  16
37  Ampicillin  1  =  4 2 8  1
37  Azithromycin  1  =  4
37  Cefotaxime  1  <=  0,25 0,03 0,12  1
37  Ceftazidime  1  <=  0,5 0,06 0,5  1
37  Chloramphenicol  1  <=  8 2 8  1
37  Ciprofloxacin  1  <=  0,015 0,004 0,015  1
37  Colistin  1  <=  1 0,25 2  1
37  Gentamicin  1  <=  0,5 0,25 1  1
37  Meropenem  1  <=  0,03 0,008 0,06  1
37  Nalidixic acid  1  <=  4 1 4  1
37  Sulfamethoxazole  1  =  32 8 32  1
37  Tetracycline  1  <=  2 0,5 2  1
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37  Trimethoprim  1  =  1 0,5 2  1
38  Ampicillin  1  =  8 2 8  1
38  Azithromycin  1  =  4
38  Cefotaxime  1  <=  0,25 0,03 0,12  1
38  Ceftazidime  1  <=  0,5 0,06 0,5  1
38  Chloramphenicol  1  <=  8 2 8  1
38  Ciprofloxacin  1  <=  0,015 0,004 0,015  1
38  Colistin  1  <=  1 0,25 2  1
38  Gentamicin  1  <=  0,5 0,25 1  1
38  Meropenem  1  <=  0,03 0,008 0,06  1
38  Nalidixic acid  1  <=  4 1 4  1
38  Sulfamethoxazole  1  =  32 8 32  1
38  Tetracycline  1  <=  2 0,5 2  1
38  Tigecycline  1  <=  0,25 0,03 0,25  1
38  Trimethoprim  1  =  0,5 0,5 2  1
38  Cefepime  2  <=  0,06 0,015 0,12  1
38  Cefotaxime  2  <=  0,25 0,03 0,12  1
38 
Cefotaxime/clavulanic 
acid  2  <=  0,06
38  Cefoxitin  2  =  2 2 8  1
38  Ceftazidime  2  <=  0,25 0,06 0,5  1
38 
Ceftazidime/clavulanic 
acid  2  <=  0,12
38  Ertapenem  2  <=  0,015 0,004 0,015  1
38  Imipenem  2  =  0,25 0,06 0,25  1
38  Meropenem  2  <=  0,03 0,008 0,06  1
38  Temocillin  2  =  16
39  Ampicillin  1  =  8 2 8  1
39  Azithromycin  1  =  4
39  Cefotaxime  1  <=  0,25 0,03 0,12  1
39  Ceftazidime  1  <=  0,5 0,06 0,5  1
39  Chloramphenicol  1  <=  8 2 8  1
39  Ciprofloxacin  1  <=  0,015 0,004 0,015  1
39  Colistin  1  <=  1 0,25 2  1
39  Gentamicin  1  <=  0,5 0,25 1  1
39  Meropenem  1  <=  0,03 0,008 0,06  1
39  Nalidixic acid  1  <=  4 1 4  1
39  Sulfamethoxazole  1  =  16 8 32  1
39  Tetracycline  1  <=  2 0,5 2  1
39  Tigecycline  1  <=  0,25 0,03 0,25  1
39  Trimethoprim  1  =  0,5 0,5 2  1
39  Cefepime  2  <=  0,06 0,015 0,12  1




LAB  ANTIMICROBIAL  PANEL  OPERATOR VALUE  MIN_VALUE MAX_VALUE  SCORE
39  Cefoxitin  2  =  4 2 8  1
39  Ceftazidime  2  <=  0,25 0,06 0,5  1
39  Ertapenem  2  <=  0,015 0,004 0,015  1
39  Imipenem  2  =  0,25 0,06 0,25  1
39  Meropenem  2  <=  0,03 0,008 0,06  1
39  Temocillin  2  =  16
40  Ampicillin  1  =  2 2 8  1
40  Cefotaxime  1  =  0,12 0,03 0,12  1
40  Ceftazidime  1  =  0,5 0,06 0,5  1
40  Chloramphenicol  1  =  8 2 8  1
40  Ciprofloxacin  1  =  0,015 0,004 0,015  1
40  Colistin  1  =  1 0,25 2  1
40  Gentamicin  1  =  1 0,25 1  1
40  Meropenem  1  =  0,06 0,008 0,06  1
40  Nalidixic acid  1  =  4 1 4  1
40  Sulfamethoxazole  1  =  32 8 32  1
40  Tetracycline  1  =  2 0,5 2  1
40  Tigecycline  1  =  0,25 0,03 0,25  1
40  Trimethoprim  1  =  0,5 0,5 2  1
40  Cefepime  2  =  0,12 0,015 0,12  1
40  Cefotaxime  2  =  0,12 0,03 0,12  1
40 
Cefotaxime/clavulanic 
acid  2  =  0,12
40  Cefoxitin  2  =  4 2 8  1
40  Ceftazidime  2  =  0,5 0,06 0,5  1
40 
Ceftazidime/clavulanic 
acid  2  =  0,5
40  Ertapenem  2  =  0,015 0,004 0,015  1
40  Imipenem  2  =  0,25 0,06 0,25  1
40  Meropenem  2  =  0,06 0,008 0,06  1
42  Ampicillin  1  =  4 2 8  1
42  Azithromycin  1  =  8
42  Cefotaxime  1  <=  0,25 0,03 0,12  1
42  Ceftazidime  1  <=  0,5 0,06 0,5  1
42  Chloramphenicol  1  <=  8 2 8  1
42  Ciprofloxacin  1  <=  0,015 0,004 0,015  1
42  Colistin  1  <=  1 0,25 2  1
42  Gentamicin  1  <=  0,5 0,25 1  1
42  Meropenem  1  <=  0,03 0,008 0,06  1
42  Nalidixic acid  1  <=  4 1 4  1
42  Sulfamethoxazole  1  =  32 8 32  1
42  Tetracycline  1  <=  2 0,5 2  1




LAB  ANTIMICROBIAL  PANEL  OPERATOR VALUE  MIN_VALUE MAX_VALUE  SCORE
42  Trimethoprim  1  =  0,5 0,5 2  1
42  Cefepime  2  <=  0,06 0,015 0,12  1
42  Cefotaxime  2  <=  0,25 0,03 0,12  1
42  Cefoxitin  2  =  4 2 8  1
42  Ceftazidime  2  <=  0,25 0,06 0,5  1
42  Ertapenem  2  <=  0,015 0,004 0,015  1
42  Imipenem  2  <=  0,12 0,06 0,25  1
42  Meropenem  2  <=  0,03 0,008 0,06  1
42  Temocillin  2  =  8
45  Ampicillin  1  =  2 2 8  1
45  Azithromycin  1  <=  2
45  Cefotaxime  1  <=  0,25 0,03 0,12  1
45  Ceftazidime  1  <=  0,5 0,06 0,5  1
45  Chloramphenicol  1  <=  8 2 8  1
45  Ciprofloxacin  1  <=  0,015 0,004 0,015  1
45  Colistin  1  <=  1 0,25 2  1
45  Gentamicin  1  <=  0,5 0,25 1  1
45  Meropenem  1  <=  0,03 0,008 0,06  1
45  Nalidixic acid  1  <=  4 1 4  1
45  Sulfamethoxazole  1  =  16 8 32  1
45  Tetracycline  1  <=  2 0,5 2  1
45  Tigecycline  1  <=  0,25 0,03 0,25  1
45  Trimethoprim  1  =  0,5 0,5 2  1
45  Cefepime  2  <=  0,06 0,015 0,12  1
45  Cefotaxime  2  <=  0,25 0,03 0,12  1
45 
Cefotaxime/clavulanic 
acid  2  <=  0,06
45  Cefoxitin  2  =  4 2 8  1
45  Ceftazidime  2  <=  0,25 0,06 0,5  1
45 
Ceftazidime/clavulanic 
acid  2  <=  0,12
45  Ertapenem  2  <=  0,015 0,004 0,015  1
45  Imipenem  2  <=  0,12 0,06 0,25  1
45  Meropenem  2  <=  0,03 0,008 0,06  1
45  Temocillin  2  =  8
56  Ampicillin  1  =  4 2 8  1
56  Azithromycin  1  =  4
56  Cefotaxime  1  <=  0,25 0,03 0,12  1
56  Ceftazidime  1  <=  0,5 0,06 0,5  1
56  Chloramphenicol  1  <=  8 2 8  1
56  Ciprofloxacin  1  <=  0,015 0,004 0,015  1
56  Colistin  1  <=  1 0,25 2  1




LAB  ANTIMICROBIAL  PANEL  OPERATOR VALUE  MIN_VALUE MAX_VALUE  SCORE
56  Meropenem  1  <=  0,03 0,008 0,06  1
56  Nalidixic acid  1  <=  4 1 4  1
56  Sulfamethoxazole  1  =  32 8 32  1
56  Tetracycline  1  <=  2 0,5 2  1
56  Tigecycline  1  <=  0,25 0,03 0,25  1
56  Trimethoprim  1  =  0,5 0,5 2  1
56  Cefepime  2  <=  0,06 0,015 0,12  1
56  Cefotaxime  2  <=  0,25 0,03 0,12  1
56 
Cefotaxime/clavulanic 
acid  2  <=  0,06
56  Cefoxitin  2  =  2 2 8  1
56  Ceftazidime  2  <=  0,25 0,06 0,5  1
56 
Ceftazidime/clavulanic 
acid  2  <=  0,12
56  Ertapenem  2  <=  0,015 0,004 0,015  1
56  Imipenem  2  <=  0,12 0,06 0,25  1
56  Meropenem  2  <=  0,03 0,008 0,06  1
56  Temocillin  2  =  8
58  Ampicillin  1  =  8 2 8  1
58  Azithromycin  1  =  8
58  Cefotaxime  1  <=  0,25 0,03 0,12  1
58  Ceftazidime  1  <=  0,5 0,06 0,5  1
58  Chloramphenicol  1  <=  8 2 8  1
58  Ciprofloxacin  1  <=  0,015 0,004 0,015  1
58  Colistin  1  <=  1 0,25 2  1
58  Gentamicin  1  =  1 0,25 1  1
58  Meropenem  1  <=  0,03 0,008 0,06  1
58  Nalidixic acid  1  <=  4 1 4  1
58  Sulfamethoxazole  1  =  32 8 32  1
58  Tetracycline  1  <=  2 0,5 2  1
58  Tigecycline  1  <=  0,25 0,03 0,25  1
58  Trimethoprim  1  =  0,5 0,5 2  1
58  Cefepime  2  <=  0,06 0,015 0,12  1
58  Cefotaxime  2  <=  0,25 0,03 0,12  1
58 
Cefotaxime/clavulanic 
acid  2  <=  0,06
58  Cefoxitin  2  =  4 2 8  1
58  Ceftazidime  2  =  0,5 0,06 0,5  1
58 
Ceftazidime/clavulanic 
acid  2  =  0,25
58  Ertapenem  2  <=  0,015 0,004 0,015  1
58  Imipenem  2  <=  0,12 0,06 0,25  1




LAB  ANTIMICROBIAL  PANEL  OPERATOR VALUE  MIN_VALUE MAX_VALUE  SCORE
58  Temocillin  2  =  32
60  Ampicillin  1  =  4 2 8  1
60  Azithromycin  1  =  4
60  Cefotaxime  1  <=  0,25 0,03 0,12  1
60  Ceftazidime  1  <=  0,5 0,06 0,5  1
60  Chloramphenicol  1  <=  8 2 8  1
60  Ciprofloxacin  1  <=  0,015 0,004 0,015  1
60  Colistin  1  <=  1 0,25 2  1
60  Gentamicin  1  <=  0,5 0,25 1  1
60  Meropenem  1  <=  0,03 0,008 0,06  1
60  Nalidixic acid  1  <=  4 1 4  1
60  Sulfamethoxazole  1  <=  8 8 32  1
60  Tetracycline  1  <=  2 0,5 2  1
60  Tigecycline  1  <=  0,25 0,03 0,25  1
60  Trimethoprim  1  <=  0,25 0,5 2  0
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Appendix 7a- Summary of results Enterococci trial 
AB EURL ENT-9.1  EURL ENT-9.2  EURL ENT-9.3  EURL ENT-9.4  EURL ENT-9.5  EURL ENT-9.6  EURL ENT-9.7  EURL ENT-9.8  
 tested correct tested correct tested correct tested correct tested correct tested correct tested correct tested correct 
AMP 26 25 26 25 26 25 26 26 24 20 26 26 26 26 26 26 
CHL 27 27 27 26 26 26 27 27 27 27 27 27 26 26 27 27 
CIP 24 24 24 24 24 24 24 24 24 24 24 24 24 24 24 24 
DAP 22 22 22 22 22 22     22 22 22 22 21 21 21 21 
ERY 27 26 27 27 27 27 27 27 27 27 27 27 27 26 27 27 
GEN 26 26 27 27 26 26 27 27 27 27 27 27 27 27 27 27 
LZD 27 27 27 27 27 27 27 27 27 27 27 27 27 27 27 27 
SYN                 21 20             
TEI 23 23 23 23 23 23 23 23 22 22 23 23 23 23 23 23 
TET 27 27 27 27 27 27 27 26 26 26 27 27 27 27 27 27 
TGC 22 19 22 20     22 20 22 21 22 19 22 18 22 20 
VAN 27 27 27 27 27 27 27 27 27 27 27 27 27 27 27 27 
Total 278 273 279 275 276 269 257 254 296 290 279 276 277 272 278 276 

















AMP 1 3,8% 1 3,8% 1 3,8% 0 0,0% 4 16,7% 0 0,0% 0 0,0% 0 0,0% 
CHL 0 0,0% 1 3,7% 0 0,0% 0 0,0% 0 0,0% 0 0,0% 0 0,0% 0 0,0% 
CIP 0 0,0% 0 0,0% 0 0,0% 0 0,0% 0 0,0% 0 0,0% 0 0,0% 0 0,0% 
DAP 0 0,0% 0 0,0% 0 0,0% 0 NA 0 0,0% 0 0,0% 0 0,0% 0 0,0% 
ERY 1 3,7% 0 0,0% 0 0,0% 0 0,0% 0 0,0% 0 0,0% 1 3,7% 0 0,0% 
GEN 0 0,0% 0 0,0% 0 0,0% 0 0,0% 0 0,0% 0 0,0% 0 0,0% 0 0,0% 
LZD 0 0,0% 0 0,0% 0 0,0% 0 0,0% 0 0,0% 0 0,0% 0 0,0% 0 0,0% 
SYN     0 NA     0 NA 1 4,8%             
TEI 0 0,0% 0 0,0% 0 0,0% 0 0,0% 0 0,0% 0 0,0% 0 0,0% 0 0,0% 
TET 0 0,0% 0 0,0% 0 0,0% 1 3,7% 0 0,0% 0 0,0% 0 0,0% 0 0,0% 
TGC 3 13,6% 2 9,1% 0 NA 2 9,1% 1 4,5% 3 13,6% 4 18,2% 2 9,1% 
VAN 0 0,0% 0 0,0% 0 0,0% 0 0,0% 0 0,0% 0 0,0% 0 0,0% 0 0,0% 
  Combinations subtracted from report as they caused more than 25% deviation 
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       Appendix 7b- Summary of results Staphylococci trial 
AB EURL ST-9.1 EURL ST-9.2 EURL ST-9.3 EURL ST-9.4 EURL ST-9.5 EURL ST-9.6 EURL ST-9.7 EURL ST-9.8 
 
tested correct tested correct tested correct tested correct tested correct tested correct tested correct tested correct 
 FOX 23 23 23 23 23 23 23 23 23 23 23 23 23 23 23 23 
 CHL 24 24 24 24 24 24 24 24 24 24 24 23 24 24 24 23 
 CIP 24 24 24 24 24 24 
  
24 24 24 24 24 24 24 24 
 CLN 24 24 24 24 24 24 24 19 22 22 24 22 24 24 24 24 
 ERY 25 25 24 22 24 24 25 21 25 25 25 25 25 25 25 25 
 GEN 24 24 24 24 24 24 24 23 24 23 24 24 24 24 24 24 
 LZD 21 21 21 21 21 21 20 20 21 21 21 20 21 21 21 21 
 MUP 19 19 19 19 19 19 19 19 19 19 19 19 19 19 19 19 
 SYN 19 19 18 17 17 15 18 16 
  
18 18 18 18 18 18 
 SMX 20 19 20 20 20 20 19 18 20 20 20 20 20 20 20 20 
 SXT 6 6 5 5 5 5 5 5 6 6 6 6 6 6 5 5 
 TET 25 25 25 25 25 25 25 25 25 23 24 24 25 25 25 25 
 TIA 18 18 17 17 19 19 17 15 18 18 18 17 18 18 18 18 
 TMP 24 23 24 24 24 24 24 23 24 23 24 24 24 22 24 24 
 VAN 20 20 21 21 21 21 21 21 20 20 20 20 20 20 20 20 
Total 316 314 313 310 314 312 288 272 295 291 314 309 315 313 314 313 
 
dev per dev dev per dev dev per dev dev per dev dev per dev dev per dev dev per dev dev per dev 
 FOX 0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 
 CHL 0 0% 0 0% 0 0% 0 0% 0 0% 1 4% 0 0% 1 4% 
 CIP 0 0% 0 0% 0 0% 0 NA 0 0% 0 0% 0 0% 0 0% 
 CLN 0 0% 0 0% 0 0% 5 21% 0 0% 2 8% 0 0% 0 0% 
 ERY 0 0% 2 8% 0 0% 4 16% 0 0% 0 0% 0 0% 0 0% 
 GEN 0 0% 0 0% 0 0% 1 4% 1 4% 0 0% 0 0% 0 0% 
 LZD 0 0% 0 0% 0 0% 0 0% 0 0% 1 5% 0 0% 0 0% 
 MUP 0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 
 SYN 0 0% 1 6% 2 12% 2 11% 0 NA 0 0% 0 0% 0 0% 
 SMX 1 5% 0 0% 0 0% 1 5% 0 0% 0 0% 0 0% 0 0% 
 SXT 0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 
 TET 0 0% 0 0% 0 0% 0 0% 2 8% 0 0% 0 0% 0 0% 
 TIA 0 0% 0 0% 0 0% 2 12% 0 0% 1 6% 0 0% 0 0% 
 TMP 1 4% 0 0% 0 0% 1 4% 1 4% 0 0% 2 8% 0 0% 
 VAN 0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 





      Appendix 7c- Summary of results E. coli trial 
 
  EURL EC‐9.1  EURL EC‐9.2  EURL EC‐9.3  EURL EC‐9.4  EURL EC‐9.5  EURL EC‐9.6  EURL EC‐9.7  EURL EC‐9.8 
tested  correct tested correct  tested correct tested correct tested correct tested correct tested correct tested correct
 AMP  31  31 31 31  31 30 31 30 31 31 30 29 31 31 31 31
 AZI  29  28 29 29  28 28 28 28 28 28 28 28 29 29 28 28
 FEP  23  18 30 30 30 27 31 30 31 31 31 31
 FOT  54  48 31 31  61 60 61 61 62 61 30 29 62 62 62 62
 FOX  23  22 30 30 31 31 30 30 31 31 31 30
 TAZ  54  54 31 31  61 60 62 62 62 62 30 28 62 62 62 62
 CHL  30  30 31 30  31 31 31 31 31 31 30 29 31 31 29 27
 CIP  31  31 31 31  31 31 31 31 31 31 30 29 31 31 31 31
 COL  31  31 31 31  31 31 31 31 31 30 30 30 31 31 31 31
 ETP  23  23 30 29 31 31 31 31 31 31 31 31
 GEN  31  31 31 31  31 31 31 31 31 31 30 29 31 31 31 31
 IMI  22  20 30 30 31 31 31 31 31 31 31 31
 MERO  54  36 31 31  61 61 62 61 61 61 30 30 62 62 62 62
 NAL  31  31 31 31  31 31 31 31 31 29 30 30 31 31 31 31
 SMX  31  31 31 30  31 31 31 31 31 31 30 27 31 31 31 31
 TET  31  31 31 31  31 31 31 31 31 31 30 29 31 31 31 31
 TGC  31  31 31 31  31 31 31 31 31 31 30 30 31 31 31 31
 TMP  31  30 30 30  31 31 31 31 31 31 30 30 31 31 31 30
Total  591  557 431 429  641 637 646 641 646 641 418 407 649 649 646 642
AB  dev 
per 











 AMP  0  0% 0 0%  1 3% 1 3% 0 0% 1 3% 0 0% 0 0%
 AZI  1  3% 0 0%  0 0% 0 0% 0 0% 0 0% 0 0% 0 0%
 FEP  5  22% 0 0%  0 0% 3 10% 1 3% 0 0% 0 0% 0 0%
 FOT  6  11% 0 0%  1 2% 0 0% 1 2% 1 3% 0 0% 0 0%
 FOX  1  4% 0 0%  0 0% 0 0% 0 0% 0 0% 0 0% 1 3%
 TAZ  0  0% 0 0%  1 2% 0 0% 0 0% 2 7% 0 0% 0 0%
 CHL  0  0% 1 3%  0 0% 0 0% 0 0% 1 3% 0 0% 2 7%
 CIP  0  0% 0 0%  0 0% 0 0% 0 0% 1 3% 0 0% 0 0%
 COL  0  0% 0 0%  0 0% 0 0% 1 3% 0 0% 0 0% 0 0%
 ETP  0  0% 0 0%  1 3% 0 0% 0 0% 0 0% 0 0% 0 0%
 GEN  0  0% 0 0%  0 0% 0 0% 0 0% 1 3% 0 0% 0 0%
 IMI  2  9% 0 0%  0 0% 0 0% 0 0% 0 0% 0 0% 0 0%
 MERO  18  33,3% 0 0%  0 0% 1 2% 0 0% 0 0% 0 0% 0 0%




 SMX  0  0% 1 3%  0 0% 0 0% 0 0% 3 10% 0 0% 0 0%
 TET  0  0% 0 0%  0 0% 0 0% 0 0% 1 3% 0 0% 0 0%
 TGC  0  0% 0 0%  0 0% 0 0% 0 0% 0 0% 0 0% 0 0%
 TMP  1  3% 0 0%  0 0% 0 0% 0 0% 0 0% 0 0% 1 3%
 Combination subtracted from report as it caused more than 25% deviations. 
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Appendix 8a- Deviations of results Enterococci trial 
 
LAB STRAINID ANTIMICROBIAL EXP_INTERP INTERP READVALUE EXPVAL 
2 EURL ENT-9.2 Tigecycline TGC S R 0,5 0,25 
2 EURL ENT-9.3 Tigecycline TGC S R 0,5 0,25 
2 EURL ENT-9.4 Daptomycin DAP R S 4 8 
2 EURL ENT-9.7 Tigecycline TGC S R 0,5 0,25 
9 EURL ENT-9.4 Daptomycin DAP R S 4 8 
11 EURL ENT-9.4 Daptomycin DAP R S 4 8 
12 EURL ENT-9.1 Ampicillin AMP S R 16 1 
12 EURL ENT-9.2 Ampicillin AMP S R 32 1 
12 EURL ENT-9.3 Ampicillin AMP S R 16 1 
12 EURL ENT-9.5 Ampicillin AMP S R 8 4 
16 EURL ENT-9.4 Daptomycin DAP R S 4 8 
16 EURL ENT-9.5 Ampicillin AMP S R 8 4 
17 EURL ENT-9.4 Daptomycin DAP R S 4 8 
19 EURL ENT-9.1 Tigecycline TGC S R 0,5 0,25 
19 EURL ENT-9.3 Tigecycline TGC S R 0,5 0,25 
19 EURL ENT-9.4 Daptomycin DAP R S 2 8 
19 EURL ENT-9.4 Tigecycline TGC S R 0,5 0,25 
19 EURL ENT-9.6 Tigecycline TGC S R 0,5 0,25 
19 EURL ENT-9.7 Tigecycline TGC S R 0,5 0,25 
19 EURL ENT-9.8 Tigecycline TGC S R 0,5 0,25 
20 EURL ENT-9.4 Quinopristin-dalfopristin (Synercid) SYN S R 8 4 
20 EURL ENT-9.5 Quinopristin-dalfopristin (Synercid) SYN S R 4 4 
22 EURL ENT-9.4 Daptomycin DAP R S 2 8 
23 EURL ENT-9.4 Daptomycin DAP R S 2 8 
25 EURL ENT-9.4 Daptomycin DAP R S 2 8 
25 EURL ENT-9.5 Ampicillin AMP S R 8 4 
26 EURL ENT-9.4 Daptomycin DAP R S 2 8 
26 EURL ENT-9.4 Quinopristin-dalfopristin (Synercid) SYN S R 8 4 
29 EURL ENT-9.3 Tigecycline TGC S R 0,5 0,25 
29 EURL ENT-9.4 Daptomycin DAP R S 2 8 
29 EURL ENT-9.7 Tigecycline TGC S R 0,5 0,25 
30 EURL ENT-9.4 Daptomycin DAP R S 2 8 
34 EURL ENT-9.1 Erythromycin ERY R S <=1 >   128 
34 EURL ENT-9.4 Daptomycin DAP R S 2 8 
34 EURL ENT-9.4 Quinopristin-dalfopristin (Synercid) SYN S R 8 4 
34 EURL ENT-9.7 Erythromycin ERY R S <=1 >   128 
36 EURL ENT-9.4 Daptomycin DAP R S 4 8 
38 EURL ENT-9.1 Tigecycline TGC S R 0,5 0,25 
38 EURL ENT-9.3 Tigecycline TGC S R 0,5 0,25 
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LAB STRAINID ANTIMICROBIAL EXP_INTERP INTERP READVALUE EXPVAL 
38 EURL ENT-9.6 Tigecycline TGC S R 0,5 0,25 
40 EURL ENT-9.2 Chloramphenicol CHL R S <4 128 
40 EURL ENT-9.4 Daptomycin DAP R S 1 8 
40 EURL ENT-9.4 Tetracycline TET R S 2 128 
42 EURL ENT-9.1 Tigecycline TGC S R 1 0,25 
42 EURL ENT-9.2 Tigecycline TGC S R 0,5 0,25 
42 EURL ENT-9.3 Tigecycline TGC S R 0,5 0,25 
42 EURL ENT-9.4 Daptomycin DAP R S 4 8 
42 EURL ENT-9.4 Quinopristin-dalfopristin (Synercid) SYN S R 8 4 
42 EURL ENT-9.4 Tigecycline TGC S R 0,5 0,25 
42 EURL ENT-9.5 Ampicillin AMP S R 8 4 
42 EURL ENT-9.5 Tigecycline TGC S R 1 0,12 
42 EURL ENT-9.6 Tigecycline TGC S R 0,5 0,25 
42 EURL ENT-9.7 Tigecycline TGC S R 0,5 0,25 
42 EURL ENT-9.8 Tigecycline TGC S R 0,5 0,25 
45 EURL ENT-9.3 Tigecycline TGC S R 0,5 0,25 
45 EURL ENT-9.4 Daptomycin DAP R S 2 8 
56 EURL ENT-9.4 Daptomycin DAP R S 4 8 
56 EURL ENT-9.4 Quinopristin-dalfopristin (Synercid) SYN S R 8 4 
58 EURL ENT-9.4 Daptomycin DAP R S 4 8 
58 EURL ENT-9.4 Quinopristin-dalfopristin (Synercid) SYN S R 8 4 
60 EURL ENT-9.4 Daptomycin DAP R S 4 8 
60 EURL ENT-9.4 Quinopristin-dalfopristin (Synercid) SYN S R 8 4 
 Combinations subtracted from report as they  caused more than 25% 
deviation. 
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Appendix 8b- Deviations of results Staphylococci trial 
LAB STRAINID ANTIMICROBIAL EXP_INTERP INTERP READVALUE EXPVAL 
2 EURL ST-9.4 Ciprofloxacin CIP R S 1 2 
2 EURL ST-9.5 Quinopristin-dalfopristin (Synercid) SYN S R 2 1 
11 EURL ST-9.1 Trimethoprim TMP S R >32 <=  0.5 
11 EURL ST-9.4 Ciprofloxacin CIP R S 1 2 
11 EURL ST-9.4 Clindamycin CLN S R >32 0,12 
11 EURL ST-9.4 Erythromycin ERY S R >32 0,25 
12 EURL ST-9.4 Ciprofloxacin CIP R S 0,5 2 
17 EURL ST-9.5 Gentamicin GEN S R 4 0,5 
17 EURL ST-9.5 Quinopristin-dalfopristin (Synercid) SYN S R 2 1 
17 EURL ST-9.6 Chloramphenicol CHL S R 32 8 
17 EURL ST-9.6 Linezolid LZD S R 8 4 
19 EURL ST-9.2 Erythromycin ERY S R >8 0,25 
19 EURL ST-9.4 Ciprofloxacin CIP R S 1 2 
20 EURL ST-9.5 Quinopristin-dalfopristin (Synercid) SYN S R 2 1 
20 EURL ST-9.5 Tetracycline TET S R 2 0,5 
21 EURL ST-9.4 Ciprofloxacin CIP R S 1 2 
22 EURL ST-9.4 Ciprofloxacin CIP R S 1 2 
22 EURL ST-9.4 Clindamycin CLN S R >4 0,12 
22 EURL ST-9.4 Erythromycin ERY S R >8 0,25 
22 EURL ST-9.4 Quinopristin-dalfopristin (Synercid) SYN S R >4 <=  0.5 
22 EURL ST-9.4 Tiamulin TIA S R >4 0,5 
22 EURL ST-9.4 Trimethoprim TMP S R 4 1 
22 EURL ST-9.5 Quinopristin-dalfopristin (Synercid) SYN S R 2 1 
23 EURL ST-9.3 Quinopristin-dalfopristin (Synercid) SYN R S 1 2 
23 EURL ST-9.4 Ciprofloxacin CIP R S 1 2 
23 EURL ST-9.7 Trimethoprim TMP S R 4 1 
23 EURL ST-9.8 Chloramphenicol CHL S R 8 16 
26 EURL ST-9.5 Quinopristin-dalfopristin (Synercid) SYN S R 4 1 
29 EURL ST-9.4 Ciprofloxacin CIP R S <0.25 2 
29 EURL ST-9.4 Clindamycin CLN S R >4 0,12 
29 EURL ST-9.4 Erythromycin ERY S R >8 0,25 
29 EURL ST-9.4 Gentamicin GEN R S <1 >    16 
29 EURL ST-9.4 Quinopristin-dalfopristin (Synercid) SYN S R >4 <=  0.5 
29 EURL ST-9.4 Sulfamethoxazole SMX R S <64 256 
29 EURL ST-9.4 Tiamulin TIA S R >4 0,5 
29 EURL ST-9.5 Quinopristin-dalfopristin (Synercid) SYN S R 2 1 
29 EURL ST-9.5 Tetracycline TET S R >16 0,5 
29 EURL ST-9.5 Trimethoprim TMP S R >32 1 
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29 EURL ST-9.6 Clindamycin CLN S R 0,5 0,25 
29 EURL ST-9.6 Tiamulin TIA S R >4 1 
30 EURL ST-9.4 Ciprofloxacin CIP R S 1 2 
31 EURL ST-9.2 Quinopristin-dalfopristin (Synercid) SYN R S <=1 2 
31 EURL ST-9.3 Quinopristin-dalfopristin (Synercid) SYN R S <=1 2 
33 EURL ST-9.4 Ciprofloxacin CIP R S 0,5 2 
34 EURL ST-9.5 Quinopristin-dalfopristin (Synercid) SYN S R 2 1 
36 EURL ST-9.4 Ciprofloxacin CIP R S 1 2 
37 EURL ST-9.4 Ciprofloxacin CIP R S 1 2 
39 EURL ST-9.4 Ciprofloxacin CIP R S 1 2 
39 EURL ST-9.4 Clindamycin CLN S R >32 0,12 
39 EURL ST-9.6 Clindamycin CLN S R 1 0,25 
40 EURL ST-9.4 Ciprofloxacin CIP R S <0.25 2 
40 EURL ST-9.4 Clindamycin CLN S R >4 0,12 
40 EURL ST-9.4 Erythromycin ERY S R >8 0,25 
42 EURL ST-9.5 Quinopristin-dalfopristin (Synercid) SYN S R 2 1 
45 EURL ST-9.5 Quinopristin-dalfopristin (Synercid) SYN S R 2 1 
56 EURL ST-9.1 Sulfamethoxazole SMX S R >512 <=    32 
56 EURL ST-9.2 Erythromycin ERY S R 4 0,25 
56 EURL ST-9.7 Trimethoprim TMP S R >32 1 
58 EURL ST-9.5 Quinopristin-dalfopristin (Synercid) SYN S R 2 1 
 
 







Appendix 8c- Deviations of results E. coli trial 
 
LAB  STRAINID  PANEL  ANTIBIOTIC  READVALUE  EXPVAL  INTERP  EXP_INTERP 
2  EURL EC‐9.1  1  Meropenem MERO  0,12 0,5 S  R 
2  EURL EC‐9.1  2  Imipenem IMI  0,25 1 S  R 
2  EURL EC‐9.1  2  Meropenem MERO  0,12 0,5 S  R 
2  EURL EC‐9.6  1  Ciprofloxacin CIP  0,25 0,5 S  R 
4  EURL EC‐9.1  1  Meropenem MERO  0,12 0,5 S  R 
4  EURL EC‐9.1  2  Meropenem MERO  0,12 0,5 S  R 
6  EURL EC‐9.1  1  Cefotaxime FOT  0,5 <=  0.25  R  S 
6  EURL EC‐9.1  2  Cefotaxime FOT  0,5 <=  0.25  R  S 
11  EURL EC‐9.1  2  Cefepime FEP  0,25 0,12 R  S 
11  EURL EC‐9.1  2  Cefoxitin FOX  4 4 R  S 
12  EURL EC‐9.1  1  Cefotaxime FOT  0,5 <=  0.25  R  S 
12  EURL EC‐9.1  2  Cefepime FEP  0,25 0,12 R  S 
17  EURL EC‐9.1  1  Meropenem MERO  0,12 0,5 S  R 
17  EURL EC‐9.5  1  Nalidixic acid NAL  128 128 S  R 
17  EURL EC‐9.6  1  Gentamicin GEN  <=0.5  1 R  S 
19  EURL EC‐9.1  1  Meropenem MERO  0,12 0,5 S  R 
19  EURL EC‐9.8  2  Cefoxitin FOX  16 4 R  S 
20  EURL EC‐9.1  1  Meropenem MERO  0,12 0,5 S  R 
20  EURL EC‐9.1  2  Imipenem IMI  0,5 1 S  R 
20  EURL EC‐9.1  2  Meropenem MERO  0,12 0,5 S  R 
21  EURL EC‐9.1  1  Meropenem MERO  0,12 0,5 S  R 
21  EURL EC‐9.5  1  Nalidixic acid NAL  8 128 S  R 
23  EURL EC‐9.1  1  Meropenem MERO  0,12 0,5 S  R 
23  EURL EC‐9.4  1  Ampicillin AMP  >64  >    64  S  R 
23  EURL EC‐9.4  2  Cefepime FEP  0,12 0,25 S  R 
25  EURL EC‐9.1  2  Cefepime FEP  0,25 0,12 R  S 
25  EURL EC‐9.1  2  Cefotaxime FOT  0,5 <=  0.25  R  S 
25  EURL EC‐9.5  1  Colistin COL  <= 1  <=     1  R  S 
26  EURL EC‐9.1  1  Meropenem MERO  0,06 0,5 S  R 
26  EURL EC‐9.8  1  Chloramphenicol CHL  16 32 S  R 
29  EURL EC‐9.1  1  Meropenem MERO  0,12 0,5 S  R 
30  EURL EC‐9.4  2  Cefepime FEP  0,125 0,25 S  R 
33  EURL EC‐9.1  1  Meropenem MERO  0,06 0,5 S  R 
33  EURL EC‐9.6  1  Ampicillin AMP  >64  4 R  S 
33  EURL EC‐9.6  1  Cefotaxime FOT  4 <=  0.06  R  S 
33  EURL EC‐9.6  1  Ceftazidime TAZ  8 0,25 R  S 
33  EURL EC‐9.6  1  Chloramphenicol CHL  128 0,5 R  S 
33  EURL EC‐9.6  1  Sulfamethoxazole SMX  >1024  16 R  S 
33  EURL EC‐9.6  1  Tetracycline TET  64 4 R  S 
34  EURL EC‐9.4  2  Cefepime FEP  0,25 0,25 S  R 




LAB  STRAINID  PANEL  ANTIBIOTIC  READVALUE  EXPVAL  INTERP  EXP_INTERP 
36  EURL EC‐9.1  2  Cefepime FEP  0,25 0,12 R  S 
39  EURL EC‐9.1  1  Azithromycin AZI  <=2  >    64  S  R 
39  EURL EC‐9.1  1  Meropenem MERO  0,06 0,5 S  R 
39  EURL EC‐9.3  2  Ertapenem ETP  <=0.15  <=  0.15  R  S 
39  EURL EC‐9.4  1  Meropenem MERO  <=0.03  <=  0.03  R  S 
39  EURL EC‐9.6  1  Ceftazidime TAZ  <=4  0,25 R  S 
40  EURL EC‐9.1  1  Meropenem MERO  <0.03  0,5 S  R 
40  EURL EC‐9.1  1  Trimethoprim TMP  <0.25  >    32  S  R 
40  EURL EC‐9.6  1  Sulfamethoxazole SMX  1024 16 R  S 
40  EURL EC‐9.8  1  Chloramphenicol CHL  16 32 S  R 
40  EURL EC‐9.8  1  Trimethoprim TMP  <0.25  0,5 R  S 
42  EURL EC‐9.1  1  Meropenem MERO  0,06 0,5 S  R 
45  EURL EC‐9.1  1  Cefotaxime FOT  0,5 <=  0.25  R  S 
45  EURL EC‐9.1  2  Cefepime FEP  0,25 0,12 R  S 
45  EURL EC‐9.1  2  Cefotaxime FOT  0,5 <=  0.25  R  S 
56  EURL EC‐9.1  1  Meropenem MERO  0,12 0,5 S  R 
56  EURL EC‐9.1  2  Meropenem MERO  0,12 0,5 S  R 
56  EURL EC‐9.3  1  Ampicillin AMP  2 >    64  S  R 
56  EURL EC‐9.3  1  Cefotaxime FOT  <=0.25  64 S  R 
56  EURL EC‐9.3  1  Ceftazidime TAZ  <=0.5  2 S  R 
59  EURL EC‐9.2  1  Chloramphenicol CHL  16 8 R  S 
59  EURL EC‐9.2  1  Sulfamethoxazole SMX  1024 <=     8  R  S 
59  EURL EC‐9.5  1  Cefotaxime FOT  1 2 S  R 
59  EURL EC‐9.6  1  Sulfamethoxazole SMX  1024 16 R  S 
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